Podcast appearances and mentions of John Altman

A CAT Club presentationAN AUDIENCE WITH JOHN ALTMANJohn Altman has four Lifetime Achievement Awards and four Grammy Participation Certificates. He has composed music for over fifty movies – winning, and being nominated for BAFTAS, Golden Globes, Golden Reels and Emmy Awards long the way for Titanic, Monty Python's Life Of Brian, Goldeneye, Hear My Song, Sheltering Sky, Léon: The Professional, RKO281, The Roman Spring Of Mrs. Stone, Little Voice and No Time To Die.A gifted arranger, John has worked on 19 platinum albums, including George Michael's 1989 album Faith, which won several Grammys (he was also nominated for The Rutles film, All You Need Is Cash).Some of the artists he has written for include Simple Minds, Barry White, Tina Turner, Björk, Diana Ross, Tom Jones, Pretenders, Rod Stewart and Michael Jackson.As an in-demand woodwind player, he has played with artists as diverse as Prince, Nick Drake, Muddy Waters, Peter Green, Kevin Ayers, Amy Winehouse (whom he mentored) and he was also musical director for Hot Chocolate and Van Morrison. As a jazz musician and band leader John has played with Chet Baker, Slim Gaillard, Quincy Jones, Bud Freeman, Les McCann and many others.A renowned raconteur, Altman's acclaimed autobiography, Hidden Man was published in 2022 by Equinox.This terrific CAT Club gathering saw JASON BARNARD in the interviewer's chair doing a splendid job opposite the truly wonderful JOHN ALTMAN.Please note: John was also our guest for George Michael's Faith album. Podcast also available and well worth a listen!Happy TrailsThis event took place on 24th April 2025 in the Pigeon Loft at The Robin Hood, Pontefract, West Yorkshire.To find out more about the CAT Club please visit: www.thecatclub.co.ukThis podcast has been edited for content and for copyright reasons.Happy Trails.

Send us a textJoin me for a captivating conversation with the legendary John Altman, a true giant in the world of music. From crafting the unforgettable tunes of Monty Python to sharing stages with icons like Jimi Hendrix and Bob Marley, John's career is a testament to the power of serendipity and talent. We explore his unexpected journey, filled with fascinating stories and memorable encounters, including his humorous connection with the soap opera star of the same name. Prepare to be enthralled by tales of collaborations with Fleetwood Mac, Van Morrison, and Amy Winehouse.We even get to play out the episode with "Always Look on the Bright Side of Life!" which John arranged with Eric Idle for Monthy Python's "Life of Brian"Our musical voyage takes a nostalgic turn as we reminisce about extraordinary moments with legends like Danny Kaye and Frank Sinatra. John's anecdotes paint a vivid picture of the boisterous nights spent with these entertainment titans, and we touch on his work with Harold Nicholas during the filming of "Funny Bones." With a nod to the improvisational spirit of jazz, we delve into John's transition from saxophonist to arranger for acts like Monty Python and Hot Chocolate, capturing the whimsical and unpredictable nature of his career.In our reflections, we uncover John's love for sponge cake, classical Greek quotes, and his experiences conducting the Royal Philharmonic. He shares invaluable lessons about the importance of seizing opportunities and saying "yes" to life's surprises. As we discuss his legacy and the lasting impact of chance encounters, we celebrate John's ability to weave music and memories into a rich tapestry of creativity, leaving us inspired by a life dedicated to the art of sound.John Altman shares his extraordinary journey in the music industry, reflecting on his collaborations with iconic artists, including Monty Python and Frank Sinatra. The conversation delves into his creative process, inspirations, and the importance of storytelling through music, all underscoring Altman's legendary status as a musician and arranger.• Insights into John Altman's musical upbringing and inspirations  • Behind-the-scenes stories of arranging Monty Python's music  • Discussion on the spontaneity and adaptability in jazz and composition  • Personal anecdotes featuring notable figures in Altman's career  • Reflections on legacy, collaboration, and life lessons learned  • Altman's emphasis on creativity and its universal appealTune in next week for more stories of 'Distinction & Genius' from The Good Listening To Show 'Clearing'. If you would like to be my Guest too then you can find out HOW via the different 'series strands' at 'The Good Listening To Show' website. Show Website: https://www.thegoodlisteningtoshow.com You can email me about the Show: chris@secondcurve.uk Twitter thatchrisgrimes LinkedIn https://www.linkedin.com/in/chris-grimes-actor-broadcaster-facilitator-coach/ FaceBook Group: https://www.facebook.com/groups/842056403204860 Don't forget to SUBSCRIBE & REVIEW wherever you get your Podcasts :) Thanks for listening!

Today's episode features film composer, music arranger, orchestrator, conductor and saxophonist John Altman. Everybody knows John Altman's music, but not so many people know his name. Yet he is one of the most prolific composers, conductors and arrangers in history. This vivid account of over fifty years in the world of popular music spans the worlds of live performance, recording and composing. In all, he has composed the music for over fifty movies, and won most major film awards in his long and distinguished career. His television and recording work included all the arrangements for the Grammy-nominated Rutles. As an arranger/conductor he has worked on hit records for stars including Rod Stewart, George Michael, Tina Turner, Barry White, Diana Ross, Björk, and Alison Moyet. John has also written, produced and arranged over 4,000 commercials worldwide. Ladies and gentlemen - always look on the bright side of life - meet John Altman... If you can, please support the Electronically Yours podcast via my Patreon: patreon.com/electronicallyours

Episode 85 features John Altman who has worked with a stellar list of artists over several decades. And just to mention Jimmy Page, Van Morrison, Peter Green, Phil Collins, Jimi Hendrix, Bob Marley, George Michael, Tina Turner, Prince and Amy Winehouse would just touch the surface. Incredible stories shared of some monumental times. Learn more about your ad choices. Visit megaphone.fm/adchoices

Shoot us a Text.The second half of 2024 is rolling and we're talking about CDK's race to fully restore services in teh next 48 hours. We're also covering the drop in average EV prices below Tesla's for the first time in over a year as well as how our friends at Mohawk Chevrolet's "The Office"-inspired TikToks are taking the internet by storm.CDK Global expects its DMS to be fully restored by July 4 following cyberattacks that disrupted operations starting on July 19th for thousands of dealerships across North America.CDK has been restoring services in phases, with many dealers already back online as of July 1.Beyer Auto Group's CDK system came back online unexpectedly on July 1, which helped ease some anxiety among the staff about the indefinite outage.Despite the restoration of the core system, their customer relationship management system and third-party integrations are still not functional, causing ongoing operational challenges.Employees are now focused on the monumental task of recording all deals and service orders manually entered during the outage into the system, as explained by COO John Altman."There is some exasperation. I can see on their faces that they are just looking at this monumental task. But at least they know where they are at this point." - Said AltmanThe disruption is expected to cause a 10% drop in Q2 earnings per share for major U.S. dealership groups, potentially costing nearly $1 billion.Automakers have cut electric vehicle prices to a level below Tesla's average for the first time since early last year, driven by increased competition and market dynamics.The average transaction price of an EV, including Tesla, was $55,235 in April, $433 less than Tesla's average price.The trend continued in May, with the industry average EV price being $56,648, $721 less than Tesla's.Tesla's pricing cuts have influenced the market, pushing competitors to reduce prices or offer discounts, leading to an average discount of 12.4% on EVs in May.Despite price cuts, new Tesla registrations fell 17% in April, while EV registrations excluding Tesla grew 69%.Used EV sales have surged, growing 84% in May, as declining prices and federal tax credits make them more affordable for consumers.Mohawk Chevrolet in upstate New York has gained viral fame with a mockumentary-style TikTok series inspired by "The Office," featuring real-life dealership antics.The series, starring digital branding creators Grace Kerber and Ben Bushen, began with a video about hiding tiny ducks around the office, which went viral with nearly 2 million views for the fifth episode.The videos are created quickly, with Kerber and Bushen writing, shooting, and editing each episode in a day, leading to significant engagement and a rethink of the dealership's social strategy to focus more on TikTok."There are probably some big and funny personalities that you work with so just wing it and see what happens." - GrHosts: Paul J Daly and Kyle MountsierGet the Daily Push Back email at https://www.asotu.com/ JOIN the conversation on LinkedIn at: https://www.linkedin.com/company/asotu/ Read our most recent email at: https://www.asotu.com/media/push-back-email

This month in South Carolina, we brought our convention attendees four of retail automotive's leading minds — and now we bring them to the masses. Here's the podcast of our expert panel featuring John Altman of Beyer Auto Group; Liza Borches, former VADA chair and fourth-generation leader of Carter Myers Automotive; and automotive analyst and auto tech investor Steve Greenfield. It's all moderated by Dealer Merchant Services' Amberly Allen. The post-COVID automotive industry faces challenges and opportunities, including embracing change, adapting to new consumer preferences, and investing in resilient business models. They talk the potential of AI, the significance of culture and employee engagement, and the importance of adapting to changing customer preferences. They also highlighted concerns about margin compression, technician shortages, and the impact of government changes and tariffs.  

An Eastenders legend is among those calling on a Kent council to reopen a playing field which residents have used for more than 100 years.John Altman, who played ‘Nasty' Nick Cotton in the soap, says he “treasures” the land and that the green space should be preserved.Also in today's podcast, there are fears for the future of Kent's "music town", with some venue owners saying the town has never been so quiet.  A number of business owners are selling up as the pandemic and the cost of living crisis changes consumer habits. Hear from a wildlife expert who says a significant fall in Kent's insect numbers is ‘incredibly concerning'. Flying insect numbers have plummeted by 89% since 2004 according to a survey, which counts the number of creatures caught on vehicle number plates.A Kent school has been granted a licence for its annual fireworks display, despite neighbours' claims the sound is “absolutely insufferable.”It means the secondary will be able to sell  alcohol  and more tickets to its show. And you can find out which Kent Council makes the most out of parking charges. It comes as new figures show local authorities across the county raked in £50 million was made in just one year. 

Grammy, Bafta and Oscar winner today we have the legendary John Altman in the show

Here are a few seasonal messages from just some of the people we have had on the show: Charles Dagnall, Debbie Knight, Asif Tanvir, George Dobell, David Paynter, Ryan ten Doeschate, David Gower, Jeffrey Archer, Tymal Mills, Harry Gurney, Rikki Clarke, Nasa Hussain, Huw Turbervill, Peter Moores, Mark Pugatch, Paul Newman, Alex Stewart, Richard Clarke, Michael Carberry, Chevy Green, Chris Green, Ronnie Irani, Ben Allison, Monty Panesar, Matt Kabir Floyd, Alex Tudor, Ian King, Nasser Hussain, Ali Martin, Rishi Persad, Daren Sammy, Matthew Hoggard, Roland Butcher, John Altman, Don Topley and Mark Butcher. All the best to you and yours over Christmas and have a fantastic New Year! And don't forget to vote for us in Sports Podcast of the Year! https://www.sportspodcastgroup.com/podcast/98-not-out-the-cricket-podcast/ All the best and thank you for listening! --- Send in a voice message: https://podcasters.spotify.com/pod/show/98-not-out/message

British actor John Altman sits down with Marie Curie bereavement expert Jason Davidson to explore his experiences of death and grief.If you'd prefer, you can read a full transcript of the episode.On the Marie Curie Couch aims to open up conversations about death, break down the taboo and encourage people to share their end of life plans.This podcast is made by Marie Curie – the UK's leading end of life charity. For more information about the vital work we do, head to mariecurie.org.ukOn the Marie Curie Couch is produced and edited by Marie Curie, with support from Ultimate Content. The music featured is Time Lapse by PanOceanic. Hosted on Acast. See acast.com/privacy for more information.

GEORGE MICHAEL – FAITH with special guest JOHN ALTMAN. This interview took place before and after we listened to the vinyl album. It has to be said that John Altman is one of the great raconteurs and his stories caused many a jaw to drop in what was a truly classic CAT Club gathering. Unfortunately, George Michael didn't get much of a look in, but after listening this podcast you will understand why we've invited John back in 2024 for 'An Evening with John Altman.' So, back to George Michael's 'Faith' . . .One of the best selling albums of all time and the first album by a white solo artist to hit number one on the Billboard Top Black Albums chart.  Faith featured JOHN ALTMAN on saxophone. John is also a composer, arranger and conductor who has worked with Muddy Waters, Jimmy Page, Nick Drake, Tina Turner, Barry White, Chet Baker, Alicia Keys, Amy Winehouse, Chaka Khan, Quincy Jones, Björk, Peter Green and many, many others. His tv and film work includes James Bond Movies, Monty Python, Titanic, The Sheltering Sky, The Rutles and Léon. In the interviewer's chair, performing admirably under the circumstances, was JASON BARNARD. Happy Trails.  This event took place on 26th October 2023 in the Pigeon Loft at The Robin Hood, Pontefract, West Yorkshire. To find out more about the CAT Club please visit: www.thecatclub.co.uk This podcast has been edited for content and for copyright reasons. Happy Trails.

Composer, musician and author of "Hidden Man" John Altman joins us to remember the life of his great friend Sir Michael Parkinson, who sadly passed away yesterday (17th August 2023). John talks about his time working on the "Parkinson" tv show and the guests he encountered, such as Ingrid Bergman and also their shared love of jazz, cinema and of course cricket. Listen right to the end, as John plays us out with the "Parkinson" theme tune on his alto saxophone. --- Send in a voice message: https://podcasters.spotify.com/pod/show/98-not-out/message

John Altman is a BAFTA and EMMY winning film composer, arranger and musician. His feature films include the award-winning Little Voice, he wrote all the period music for Titanic, the classic tank chase in Goldeneye, he arranged Always Look on the Bright Side of Life from The Life Of Brian, RKO281 (EMMY winner), Hear My Song (BAFTA winner), Shall We Dance starring Richard Gere and Jennifer Lopez, Funny Bones, Vendetta, Breaking Through starring Diane Keaton, Hope Springs starring Colin Firth, Minnie Driver and Heather Graham and The Roman Spring of Mrs Stone starring Helen Mirren for which he received an EMMY Nomination. He was Van Morrison‘s MD for years and Hot Chocolate‘s MD and sax player. He's responsible for classics like Bjork‘s ‘It's Oh So Quiet', Alison Moyet‘s ‘That Old Devil Called Love' and George Michael‘s ‘Kissing A Fool', to name but a few.John Altman is guest number 263 on My Time Capsule and chats to Michael Fenton Stevens about the five things he'd like to put in a time capsule; four he'd like to preserve and one he'd like to bury and never have to think about again .Follow John Altman on Twitter: @rufusjunior .Follow My Time Capsule on Twitter, Instagram & Facebook: @MyTCpod .Follow Michael Fenton Stevens on Twitter: @fentonstevens & Instagram @mikefentonstevens .Produced and edited by John Fenton-Stevens for Cast Off Productions .Music by Pass The Peas Music .Artwork by matthewboxall.com .This podcast is proud to be associated with the charity Viva! Providing theatrical opportunities for hundreds of young people. Hosted on Acast. See acast.com/privacy for more information.

Zoals veel mensen heeft Arnoud Francken meerdere passies. Het begon met thee ('Een van de mooiste dingen die ik heb gezien, is een theeveld in de zon'). In 15 jaar bouwde hij een klein thee-imperium op, waarvan de fair trade theeproducten in 25 landen werden verkocht. Toen werd het tijd voor een andere passie: hartige snacks! Hoe die op een verantwoorde en gezonde manier aan de man te brengen? Zo kruiste zijn levenspad dat van de zussen Van der Lande, die met John Altman de bewuste consument een biologisch en verantwoorde keuze boden op het gebied van minder vette snacks. Sinds oktober 2022 mag Arnoud zich 'Chief Bites' van dat merk noemen. Vakwerk was zo gelukkig Arnoud te spreken op het moment dat John Altman met iets nieuws op de markt komt: zoete aardappel chips (in 3 smaken)! Een puur Nederlands en biologisch product. In deze editie vertelt Arnoud over zijn keuze voor de foodsector, wonderlijke belevenissen in de wereld van de thee en natuurlijk alles over John Altman. En wist je dat Arnoud piano speelt? Daar sluiten wij mee af. TIJDSCHEMA: 01:19 Introductie Arnoud Francken 04:03 Sri Lanka en thee 12:13 John Altman 17:41 Zoete aardappel chips 23:18 Waar vind je John Altman? 25:30 Arnoud's muziekkeuze 31:19 Contactgegevens SHOWNOTES: John Altman - https://johnaltman.nl Urban Nomads - https://urbannomads.club/

As Christmas approaches, here are some festive messages from some of the superb guests we've had on "98 Not Out". Thank you for listening in 2022 and we look forward to bringing you more great cricketing content in 2023. Voices you'll hear on this episode: Charles Dagnall, Asif Tanvir, George Dobell, David Paynter, Ryan ten Doeschate, David Gower, Jeffrey Archer, Tymal Mills, Harry Gurney, Rikki Clarke, Nasa Hussain, Huw Turbervill, Peter Moores, Mark Pougatch, Paul Newman, Alec Stewart, "The Grumbler", Michael Carberry, Chevy Green, Chris Green, Ronnie Irani, Ben Allison, Monty Panesar, Matt Kabir Floyd, Alex Tudor, Ian King, Nasser Hussain, Ali Martin, Rishi Persaud, Daren Sammy, Matthew Hoggard, Kyle Coetzer, Roland Butcher, John Altman, Aamir Sohail, Toby Tarrant, Don Topley and Mark Butcher. Have a great Christmas! --- Send in a voice message: https://anchor.fm/98-not-out/message

Sign up to our newsletter and never miss a release! | Visit our website John Altman has composed, arranged, conducted, produced and directed countless music for television and film including Titanic, Little Voice, Goldeneye, Leon, Peake Practice. As an arranger and conductor he's worked on hit records for artists including Rod Stewart, Diana Ross, Tina Turner, Roy Orbison, Simple Minds, George Michael. He has written, arranged and produced the music for over 4,000 commercials worldwide. He is an incredible saxophonist and has played or recorded with the likes of Little Richard, Prince, David Bowie, The Damned, Eric Clapton, Sting, Jimi Hendrix, Chet Baker, Bob Marley, Amy Winehouse, Muddy Waters, Phil Collins. The list is endless. Among others he toured with Hot Chocolate and Van Morrison as their musical director. What a life! John has such great stories to tell about his time working with the greatest icons in both the music and film industries. To them, he is the icon! Related Links and reading Hidden Man: My Many Musical Lives by John Altman  Björk - It's Oh So Quiet (Official Music Video) Goldeneye Titanic “Nearer my God to Thee” scene  Little Voice “A Star is Born”

Just back from touring the United States, singer Aoife Scott performs two live songs for us accompanied by Andy Meaney and John Altman.

John Altman is a composer, arranger and saxophonist who has done everything in music. With over 50 years in the business, John is the man behind 'Always Look on the Bright Side of Life', music for James Bond films and has worked with the likes of Van Morrison, Hans Zimmer, George Michael, David Bowie, Alison Moyet, Nick Drake and many more.

Ray speaks to Charlie Bird and wife Claire about the journalist's new book, music legend John Altman, chef Nico Reynolds and there's live music from Aoife Scott.

On today's show Prof. David O'Connell tellS us about a breakthrough in his Alzheimer's research, Prof. Anne-Marie Tobin is in studio with some advice on protecting your skin and staying sun smart and composer John Altman will be performing in the Hinterland Festival of Literature & Arts in June, he joined Ray for a chat.

Composer John Altman will be performing in the Hinterland Festival of Literature & Arts in June, he joined Ray for a chat.

Welcome to Off The Beat & Track Podcast with me Stu Whiffen.This episodes special guest is songwriter, composer, arranger and musician John AltmanI met with John remotely and we had a wonderful chat, talking about an incredible career! we discuss playing with Nick Drake, Peter Green, early gigs with Jimi Hendrix, writing some of the most know advert jingles, playing with Muddy Waters on his 21st birthday, working with George Michael, Bjork, Amy Whinehouse and Monty Python!!!!! this is some chat !!!!!Hope you enjoy this chat and if you do please feel free to support the podcast herehttps://supporter.acast.com/offthebeatandtrack orwww.patreon.com/offthebeatandtrackOTBAT is proudly sponsored by www.hotelchocolat.com Please also subscribe and follow the podcast on the social media links belowOff The Beat & Trackwww.offthebeatandtrackpodcast.comhttps://twitter.com/beatandtrackpodhttps://www.facebook.com/offthebeatandtrackpodcast/Support this show http://supporter.acast.com/offthebeatandtrack. See acast.com/privacy for privacy and opt-out information.

A Conversation with John Altman: "You cut the cloth to fit the suit!" You know his music (George Michael, Monty Python, James Bond, Simple Minds, Rod Stewart, Prefab Sprout, Tina Turner & Barry White, Diana Ross, Bjork….to cite a scant few) but likely, not his name. Dubbed “Hidden Man” by Python member Terry Gillam, John Altman is an Emmy award winning British composer, arranger, conductor – and saxophonist (Peter Green, Hot Chocolate, Van Morrison, Amy Winehouse, John Martyn, Kevin Ayers…to cite another scant few).  Hosts David C. Gross and Tom Semioli talk with this "unknown" icon who forged an indelible identity among the elite in rock, jazz, film, and television as detailed in his must-read autobiography Hidden Man: My Many Musical Lives (Equinox Publications).John Altman-The Hidden Man Playlist

John Altman: Hidden man: My many musical lives... with TRE's Giles Brown

Georgina Godwin speaks to one of the most prolific musicians and composers in the business. John Altman's work includes ‘Always Look on the Bright Side of Life' from Monty Python's ‘Life of Brian' – which he arranged, conducted and whistled – and the score for ‘Goldeneye'. His new memoir, ‘Hidden Man: My Many Musical Lives', details his extraordinary life and career.

Welcome to a new episode of the Fair Chase Podcast! Today, we talk to John Altman from Maine Hunter about the moose tag he was able to pull this year, the challenges of filming a hunt, and the similarities between hunting a whitetail deer and moose.   We also discuss: - How John's wife recently got drawn for a moose - Hunting something you're new to - When is the moose rut? - Filming content for Donnie Vincent - James' homemade moose call - What does the perfect out-of-state hunt look like? - Moose hunting strategies - Similarities between whitetail and moose - The Badlands Film festival - Cooking fresh moose loin - How does moose compare to other meats? - What's your go-to way to cook a moose? - What's John looking forward to this year? - Are you slapping moose? - Explaining our name change   VORTEX MERCHANDISE SAVE 20% - https://bit.ly/2KemVsx - TFC20 Trophy Line Tree Saddles SAVE 10%- https://bit.ly/3nN4aKu - TFC20 Vector Custom Arrow SAVE 10% - https://bit.ly/3cRh2g4 - TFC10   Other Sponsor Links: http://www.huntwise.com/ www.bivouacbowco.com https://www.g5prime.com

Pastor Craig and church deacon, John Altman, have an interactive discussion today on how to share your faith. We must listen first and not try to "win", but simply "share" the greatest gift that's ever been given to us - Jesus. --- Send in a voice message: https://anchor.fm/ferncreekcc/message Support this podcast: https://anchor.fm/ferncreekcc/support

The cursed year that was 2021 has come to an end and Lee felt like going out on a more positive note. In this mega-sized episode he's compiled a list of tracks from fictional bands and musical artists that have appeared in films. Lots of research went into this one, as Lee tries to give credit where credit is due to the people behind the fictional acts. Be it totally made up acts, parody acts that came before their film debuts, or if they actually formed later on in real life, Lee tries to cover a little of everything. He found that there's still many he could cover in later episodes, so he just might. Happy New Year, and thanks for the continued support of the show! --Sweet Talkin' Candyman & In the Long Run from "Beyond the Valley of the Dolls" (1970) --The Kelly Affair/The Carrie Nations (Lynn Carey & Barbara Robison; Stu Phillips) --Kipper & The Clapham from "Confessions of a Pop Performer" (1975) --Kipper (Ed Welch, Dominic Bugatti & Frank Musker) --Cantina Band from "Star Wars: Episode IV - A New Hope" (1977) --Figrin D'an and the Modal Nodes (John Williams) --Cheese and Onions from "The Rutles" (1978) --The Rutles (Ollie Halsall, John Altman, John Halsey, Ricky Fataar; Neil Innes) --Shama Lama Ding Dong from "Animal House" (1978) --Otis Day and the Knights (Lloyd G. Williams; Mark Davis) --She Caught the Katy from "The Blues Brothers" (1980) --The Blues Brothers (John Belushi & Dan Aykroyd; Taj Mahal & James Rachell) --Everybody Needs Somebody to Love from "The Blues Brothers" (1980) --The Blues Brothers (John Belushi & Dan Aykroyd; Bert Berns, Solomon Burke & Jerry Wexler) --Join the Professionals from "Ladies and Gentlemen, The Fabulous Stains" (1982) --The Stains (Diane Lane; Paul Cook & Steve Jones) --Waste of Time from "Ladies and Gentlemen, The Fabulous Stains" (1982) --The Stains (Diane Lane; Barry Ford & Nancy Dowd) --Conned Again from "Ladies and Gentlemen, The Fabulous Stains" (1982) --The Looters (Paul Cook & Steve Jones) --My Name is Mok from "Rock & Rule" (1983) --Mok (Lou Reed) --Angel's Song from "Rock & Rule" (1983) --Angel (Debby Harry) Nelvana production, also featured Cheap Trick, Lou Reed, Iggy Pop, and Earth, Wind & Fire. --You Can't Take No for an Answer from "The Muppets Take Manhattan" (1984) --Dr. Teeth and the Electric Mayhem (Jim Henson & Jeff Moss) --The Banzai Jam from "The Adventures of Buckaroo Banzai Across the 8th Dimension" (1984) --Buckaroo Banzai And The Hong Kong Cavaliers (Michael Boddicker) --Stonehenge from "This is Spinal Tap" (1984) --Spinal Tap (Christopher Guest, Michael McKean, Harry Shearer & Rob Reiner) --Stand Up from "Trick Or Treat" (1986) --Sammi Curr (Fastway) --Energy from "Rock 'n' Roll Nightmare" (1987) --The Tritonz (Thor; Peppi Marchello) --Against the Ninja from "Miami Connection" (1987) --Dragon Sound (Angelo Janotti & Kathy Collier) --Dance on Fire from "Black Roses" (1988) --Black Roses (King Kobra) --Something's Gonna Die Tonight & Who the Hell Do You Think You Are? from "Hard Core Logo" (1996) --Hard Core Logo (Hugh Dillon & Swamp Baby) --Pina Coladaburg from "Club Dread" (2004) --Coconut Pete (Bill Paxton, Nathan Barr) --Inside of You from "Forgetting Sarah Marshall" (2008) --Infant Sorrow (Russell Brand; Jason Segel, Peter Salett & Lyle Workman) --What Have I Become from "Green Room" (2015) --The Aint Rights (Anton Yelchin, Alia Shawkat, Joe Cole, Callum Turner; Human Brains) Opening and closing music: Magic and Ecstasy from "Exorcist II: The Heretic" by Ennio Morricone, and The Shadow of the Killer from "Death Rage" by Guido & Maurizio De Angelis.

Just chopsing today with eastenders bad boy John Altman about his new music, his life growing up with the punk stars of the 70's, his time spent in a Belgian prison and can you guess how many years he spent on T.V as nasty Nick Cotton? We had a great time chopsing with Nick about his minor movie roles in Star Wars Return of the jedi, An American werewolf in London and much more.

Barry Richards in conversatio with John Altman who played nasty Nick Cotton from Eastenders talking about his acting and music.

We caught up with John Altman, fresh from his work on the soundtrack for the new Bond film "No Time To Die" and ask him about his links with the 007 movie franchise and the blockbuster films he has contributed to, such as "Goldeneye", "Titanic" and "Monty Python's Life of Brian"! When he is not scoring film soundtracks or producing artists such as George Michael, Simple Minds, Amy Winehouse and Alison Moyet, John has a huge passion for cricket and in this conversation, we scratch the surface of his many anecdotes and ask how he became the unofficial social secretary for the Australian cricket team, unlikely Hollywood cricket fans and his thoughts on England heading Down Under this winter.

Listen to Kimi FM News Update from VOA Jazz Corner bersama TonTham Tony Thamrin,Minggu 17 Oktober 2021 akan menyuguhkan aneka lagu jazz pilihan dan juga sejumlah informasi menarik seputar dunia jazz. Salah satunya,kabar dari Film James Bond terbaru "No Time To Die" telah dirilis di Amerika 8 Oktober lalu. Movie Soundtrack yang dibintangi oleh Daniel Craig,kali ini akan bernuansa Musik Jazz dan musik tersebut di arahkan oleh John Altman,seorang musisi jazz dari London-Inggris berusia 71 tahun. Simak liputan lengkap Listen to Kimi FM News Update from VOA Jazz Corner langsung dari Washington DC-Amerika Serikat.

In the second edition of this two-part Oncology, Etc. episode, hosts Dr. Patrick Loehrer (Indiana University) and Dr. David Johnson (University of Texas) continue their conversation with Dr. Otis Brawley, a distinguished professor of Oncology at Johns Hopkins and former Executive Vice President of the American Cancer Society. Subscribe: Apple Podcasts, Google Podcasts | Additional resources: elearning.asco.org | Contact Us Air Date: 10/5/2021   TRANSCRIPT [MUSIC PLAYING] SPEAKER: The purpose of this podcast is to educate and inform. This is not a substitute for medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. [MUSIC PLAYING] DAVID JOHNSON: Welcome back to Oncology, Etc, and our second segment of our conversation with Otis Brawley, professor of Medicine at Johns Hopkins Medical School and the Bloomberg School of Public Health. Pat, I don't know about you, but Otis is a very impressive man, and he had a lot of really interesting things to say about his career development, family, et cetera in the first segment. This second segment, we're going to get to hear more about his time at the ACS. What were your thoughts about segment one? PATRICK LOEHRER: Well, I loved talking to Otis, and you too, Dave. Parenthetically, Otis once told me in a dinner conversation we had that he felt like Forrest Gump, and I can identify with that. Where over the field, our field of oncology over the last several decades, we've met some incredibly wonderful people, and we've been lucky to be part of the history. The three of us, I think, do have a deep sense of the historical context of oncology. This is a young field, and there's just some extraordinary people, many of them real true heroes, and Otis has his figure on the pulse of that. DAVID JOHNSON: Yeah, that's why he's been in some of the right places at the right time, and we'll hear more about that in this segment coming up now. PATRICK LOEHRER: Now Otis has had a career in many different areas, including ODAC, the NCI, the ACS, now at Hopkins. So let's hear a little bit more about Dr. Brawley's experience at the American Cancer Society and particularly with his experience with the former CEO, John Seffrin. DAVID JOHNSON: Sounds great. [MUSIC PLAYING] OTIS BRAWLEY: John and I had a wonderful run at the American Cancer Society. Got to do a lot of things. Got to testify for the Affordable Care Act. Got to do some of the science to actually argue that the Affordable Care Act would help. And I was fortunate enough to be there long enough to do some of the science to show that the Affordable Care Act is helping. DAVID JOHNSON: Yeah, I mean actually all of the things you accomplished at the ACS are truly amazing. Let me ask you, just on a personal level, what did you like most about that job, and then what did you like least about that job? [LAUGHTER] OTIS BRAWLEY: I like the fact-- there were a lot of things I liked about that job. There were a couple hundred scientists and scientific support people that you got to work with. And I used to always say, I do politics so you can do science. And what I used to like the most, every Wednesday afternoon that I was in town, I would walk around just to watch those people think. I used to joke around and say, I'm just walking around to see who came to work today. But I really enjoyed watching them work and watching them think, and that was fun. Another fun aspect of the job was people used to call and ask a little bit about the disease that they are a family member would have. And sitting down with them on the phone in those days-- we didn't have Zoom-- and talking to them through their disease. Not necessarily giving them advice on what to do in terms of treatment, but helping them understand the biology of the disease or connecting them with someone who was good in their disease. And I happen to, by the way, have sent some patients to both of you guys. That was a lot of fun. Then the other thing, of course, was the fact that you could actually influence policy and fix things. I'll never forget sitting across from Terry Branstad, then the governor of Iowa, and convincing him that the right thing to do is to raise the excise tax on tobacco in Iowa. Being able to see that you're effective and to see that you're positively influencing things. The bad side, some of the politics. I didn't necessarily like how some of the money was being raised or where they were raising money from. I think that you have to have a certain standard in terms of where you accept money. And we always had that tension with the fundraisers. But it's also true-- and I will give them a nod-- you can't do the fun things unless you raise money. So I really truly enjoyed my time at the American Cancer Society. And by the way, a shout out to Karen Knudsen, who is the CEO running the American Cancer Society now. And I'm fully committed to helping the ACS and helping Karen be successful. DAVID JOHNSON: One of the things I read-- I think I read this that you had said that one of your proudest accomplishments was revising the ACS screening guidelines. Tell us just a little bit about that. OTIS BRAWLEY: Yeah, going all the way back to the early 1990s, I started realizing that a lot of these guidelines for screening, or back then, this is before the NCCN guidelines for treatment even, that were published by various organizations, including the American Cancer Society. We're almost the equivalent of-- get the impression that in the 1960s, it would have been a smoke-filled room. But you gather a bunch of people into a room, and they come up with, this is what we should be doing. Indeed, the American Cancer Society in 1991 endorsed annual PSA screening for prostate cancer based purely on getting a group of primarily urologists into a room, and that's what they came up with. There was very little review of the science. There really was no science at that time except the science to show that PSA screening found cancer. There were no studies to show that led to men benefiting in that they didn't die. Indeed, in 1991, there was no study to show that treatment of early prostate cancer saved lives. The study to show treatment of prostate cancer saves lives was first published in 2003, and the radiation saves lives in 1997, 1998. Surgery saves lives in 2003 and screening has a small effect published in 2009. But they started recommending it in 1991 in this almost smoke-filled room kind of atmosphere. When I got to the American Cancer Society, I started an effort, and we involved people from the National Academy of Medicine, we involved people from the NCCN, from the American Urological Association, the American Academy of Family Physicians, the American College of Physicians. And we got together in that almost smoke-filled room again, but the idea was, how do you make responsible guidelines? And we wrote that up into a paper guide widely accepted by all of the organizations, and it involves a review of the literature that is commissioned by someone. And they spend a long time reviewing the literature and writing a literature review. And then you have a group of experts from various fields to include epidemiology and screening, social work, someone who's had the disease. Not just the surgeons and medical oncologists who treat the disease but some population scientists as well. They sit down and they reveal all of the scientific data, and then they start coming up with, we recommend this. And then they rank how strong that recommendation is based on the data. We published this in 2013 in The Journal of the American Medical Association. I do think that was important, you're right. That's Otis trying to bring his policy and his belief in orthodox approach to science and bring it all together. PATRICK LOEHRER: So let me reflect a little bit more on something. There is a book that I also just recently read by Dax-Devlon Ross, and it's a book entitled, Letters to my White Male Friends, and it was a fascinating read to me. You have this public persona and professional persona of being an outstanding physician, clinician, public speaker. But what we the three of us have never really had the conversation today is we have much more interest now in DEI. One of our other speakers talked about the fact that there's a tax that is placed upon underrepresented minorities and academics. They are all expected to be on committees. They have to be doing different things. And so the things that they love to do, they can't do it because they have to represent their race or their gender or their ethnicity. OTIS BRAWLEY: I have been blessed and fortunate. There are problems, and there are huge burdens that Black doctors, and women doctors by the way, have to carry. I have been fortunate that I have skated through without a lot of that burden. Maybe it has to do with oncology, but I will tell you that I have been helped by so many doctors, men and women, predominantly white, but some Asian, Muslim, Jewish, Christian. I don't know if it's oncology is selective of people who want to give folks a fair shake and really believe in mentoring and finding a protege and promoting their career. I have been incredibly, incredibly fortunate. Now that I say that, there are doctors, minority doctors and women, who don't have the benefits and don't have the fortunes that I have had, and we all have to be careful for that. As I said early on, John Altman told me that I will thank him by getting more Blacks and women into the old boys club. And so that was his realizing that there is a-- or there was a problem. I think there still is a problem in terms of diversity. Now I have seen personally some of the problem more outside of oncology in some of the other specialties. More in internal medicine and surgery, for example. By the way, there are also some benefit. I did well in medical school in third and fourth year in medical school at the University of Chicago because there were a group of Black nurses who were held that I wasn't going to fail. The nurses took me under their wing and taught me how to draw blood, how to pass a swan. The first code I ever called, there was a nurse standing behind me with the check off list. And so there are some advantages to being Black as well. But there are some disadvantages. I've been very fortunate. My advice to Black physicians is to keep an open mind and seek out the folks in medicine who truly do want to help you and truly do want to mentor you. And for the folks who are not minority or not women in medicine, I say, try to keep an open mind and try to help everybody equally. PATRICK LOEHRER: Thank you. DAVID JOHNSON: I want to go back to your book for a moment. And again, for those who've not read it, I would encourage them to do. So it's a really honest book, I think, well-written. You made a comment in there-- I want to make sure I quote it near correctly. You said that improvement in our health care system must be a bottom up process. What do you mean by "bottom up?" OTIS BRAWLEY: Well, much of it is driven by demand from patients and other folks. The name of the book was, How We Do Harm. And the synopsis is there are bunch of people who are harmed because they don't get the care that they need. And there's a bunch of people who are harmed because they get too much medicine and too much care. And they rob those resources away from the folks who don't get care at the same time that they're harmed by being overtreated, getting treatments that they don't need. The other thing, if I can add, in American health care, we don't stress risk reduction enough. I used to call it "prevention." Some of the survivors convince me to stress "activities to reduce risk of disease." We don't do a lot in this country in terms of diet and exercise. We try to do some work somewhat successfully on tobacco avoidance. We need to teach people how to be healthy. And if I were czar of medicine in the United States, I would try to make sure that everybody had a health coach. Many of us go to the gym and we have a trainer. We need trainers to teach us how to be healthy and how to do the right things to stay healthy. That's part of the bottom up. And in terms of costs you know my last paper that I published from the American Cancer Society, I published purposefully, this is my last paper. Ahmedin Jemal who's a wonderful epidemiologist who I happen to have worked with when I was at the National Cancer Institute and again later in my career at the American Cancer Society, I pushed Ahmedin-- he publishes these papers, and we estimate x number of people are going to be diagnosed with breast cancer and y number are going to die. He and I had talked for a long time about how college education reduces risk of cancer death dramatically. If you give a college education to a Black man, his risk of death from cancer goes down to less than the average risk for a white American. There's something about giving people college education that prevents cancer death. I simply challenged Ahmedin, calculate for me how many people in the United States would die if everybody had the risk of death of college-educated Americans. And he came back with of the 600,000 people who die in any given year, 132,000 would not die if they had all the things from prevention through screening, diagnosis, and treatment that college-educated people. Just think about that-- 132,000. Then I started trying to figure out what drug prevents 132,000 deaths per year? And I couldn't think of one until recently, and it happens to be the coronavirus vaccine. Which ironically has shown itself to be the greatest drug ever created in all of medicine. But in cancer, there's no breakthrough drug that is more effective than just simply getting every human being the care from risk reduction and prevention all the way through treatment that every human being ought to be getting. The solution to some of that starts with fixing third grade and teaching kids about exercise, about proper diet. PATRICK LOEHRER: We're going to have to wind things up here. But real quickly, a book you would recommend? OTIS BRAWLEY: Skip Trump, who's someone that we all know, wonderful guy used to run Roswell Park Cancer Center, just published a book actually it's coming out in September called, Centers of the Cancer Universe, A Half Century of Progress Against Cancer. I got a preprint of that, and it is a great book. It talks about what we've learned in oncology over the last 50 years since Richard Nixon signed the National Cancer Act. Keep in mind, he declared war on cancer on December 23, 1971. So we have an anniversary coming up in December. PATRICK LOEHRER: I want to close. Another book, I read the autobiography of Frederick Douglass. It's a wonderful read. It really is good. There were some endorsements at the end of this book, and one of them was written by a Benjamin Brawley, who wrote this review in a book called, The Negro in Literature and Art in 1921. And Benjamin Brawley was writing this about Frederick Douglass, but I would like to have you just reflect a moment. I think he was writing it about you, and I'm just going to read this. He basically said, at the time of his death in 1895, Douglass had won for himself a place of unique distinction. Large of heart and of mind, he was interested in every forward movement for his people, but his charity embraced all men in all races. His mutation was international, and today, many of his speeches are found to be the standard works of oratory. I think if your great, great grandfather were here today, he would be so incredibly proud of his protege, Otis. And it's such a privilege and pleasure to have you join us today on Oncology, Etc. Thank you so much. OTIS BRAWLEY: Thank you. And thank both of you for all the help you've given me over the years DAVID JOHNSON: Great pleasure having you today, Otis. I want to also thank all of our listeners for tuning in to Oncology, Etc. This is an ASCO educational podcast. We really are here to talk about anything and everything. So we're looking for ideas. Please, if you have any suggestions, feel free to email us at education@ASCO.org. Thanks again, and remember, Pat has a face for podcasts. [MUSIC PLAYING] SPEAKER: Thank you for listening to this week's episode of the ASCO e-learning weekly podcasts. To make us part of your weekly routine, click Subscribe. Let us know what you think by leaving a review. For more information, visit the comprehensive e-learning center at elearning.asco.org.

Episode One is all about the fantastic People's Orchestra and the work they do in the West Midlands. They've worked with young jazz phenomenon Xhosa Cole and legendary composer John Altman, who worked on the music for the new James Bond film, No Time To Die, and has composed especially for them.  We'll hear from players from The People's Orchestra whose lives have been transformed by playing music. You never know, maybe we'll inspire you join a choir or to get that instrument out of the cupboard. We hope so!  Get bonus content on Patreon Hosted on Acast. See acast.com/privacy for more information.

In this two-part episode of Oncology, Etc., hosts Dr. Patrick Loehrer (Indiana University) and Dr. David Johnson (University of Texas) speak with Dr. Otis Brawley, a Bloomberg Distinguished Professor of Oncology at Johns Hopkins and former Executive Vice President of the American Cancer Society, about his incredible life and career. Subscribe: Apple Podcasts, Google Podcasts | Additional resources: education.asco.org | Contact Us Air Date: 9/7/2021   TRANSCRIPT SPEAKER: The purpose of this podcast is to educate and inform. This is not a substitute for medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. No mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. PAT LOEHER: Hi. I'm Pat Loeher. I'm director of the Centers of Global Oncology and Health Equity at Indiana University Melbourne and Bren Simon Cancer Center. DAVID JOHNSON: And good morning. I'm Dave Johnson. I'm professor of Internal Medicine Oncology at the University of Texas Southwestern in Dallas. We're really excited to be back with the second episode of our ASCO Educational Podcast Oncology, et cetera. And I don't know about you, but my arm's really sore from entering all the fan mail we got from the first episode. Either that or maybe it was that shingles shot I got last week I don't know. PAT LOEHER: No, I agree. I really appreciate Bev. Your wife just kept texting me how wonderful I was, and it was-- I enjoyed it. DAVID JOHNSON: Well, I'm glad you mentioned that, because I wanted to read this one fan mail. It says, dear, Dave. Thanks for carrying Pat [INAUDIBLE]. I don't know who that is, but I appreciate it. PAT LOEHER: Yeah, it works both ways. Works both ways. So what have you been reading lately, Dave? DAVID JOHNSON: Well, as you know, I love to read. And actually what I'm reading right now is The Howe dynasty by Julie Flavell. It's about the brothers Howe that were involved in the Revolutionary War. But the book I finished just prior to the one I'm reading now is Adam Grant's Think Again, which I really enjoyed. It made me think again. What about you? PAT LOEHER: How many times have you read the book by the way? DAVID JOHNSON: Again. Twice. PAT LOEHER: Think again. Yeah. There was the book that's called The One Thing. I know if you saw that book which I read a while back. It took me, like, a year to do it, because I just kept doing other things while I was reading it. I felt so guilty about it. I did read the book Caste recently, and it was on Oprah Winfrey's list. Barack Obama picked it. And actually read that on my way to Kenya a couple of months ago and found it very fascinating actually. You know, the notion of the juxtaposing of Nazi Germany, of the caste system in India, and the racial struggles that was going on here in this country. And I thought it was a very well written book. DAVID JOHNSON: Yeah. You mentioned that book to me, and I finished reading it a couple of weeks ago. I agree with you. I enjoy it very much. I learned a lot. We want to introduce today's guest. We're really, really fortunate to have with us today Dr. Otis Brawley. Dr. Brawley Is the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. He's a graduate of the University of Chicago School of Medicine. He completed a residency in Internal Medicine at the University Hospitals in Cleveland Case Western Reserve and did a Fellowship in Medical Oncology at the National Cancer Institute, where he spent a good portion of his early career. In the 2000s, he relocated to Atlanta, where he became medical director of the Georgia Cancer Center for Excellence at Grady Memorial Hospital. One of the really most famous safety net hospitals in America. He was deputy director of Cancer Control at the Winship Cancer Institute of Emory University. And then he moved on to really a significant role. He became the chief medical and scientific officer and executive vise president of the American Cancer Society from 2007 to 2018, and we'll have a chance to perhaps query him about that. Currently, he leads a broad interdisciplinary research program on cancer health disparities at the Bloomberg School of Public Health and the Johns Hopkins Kimmel Cancer Center. Dr. Brawley has received innumerable awards. It would take the whole podcast to list them all. But among them are the American Medical Association Distinguished Service Award, University of Chicago Alumni of Professional Achievement Award, and-- one that I think is particularly poignant for ASCO members-- the Martin D. Abeloff Award for Excellence in Public Health and Cancer Control. In 2015, Dr. Brawley was elected to the National Academy of Medicine and well deserved. So just welcome to oncology, et cetera. Thank you so much for taking the time to be with us today. OTIS BRAWLEY: Thank you for having me. It's a pleasure to be with you and Pat. DAVID JOHNSON: Well, it's great to have you. I can tell you that. So let's just start with just a little background. Why don't you tell us about yourself? Where are you from? Where did you grow up? OTIS BRAWLEY: I grew up in Detroit. I grew up in one of the automobile worker neighborhoods, a blue collar neighborhood, and went to the Catholic schools there. The nuns in grade school pushed me toward the Jesuit school for high school, and the Jesuits in high school taught me how to think and really propelled me. And indeed much of my career, much of my writings, my philosophy toward medicine was really influenced by early education with the Jesuits. DAVID JOHNSON: Wow. PAT LOEHER: Hey, Otis. I just want to throw in-- in terms of books that we've read, one of the other books that I want to give a shout out is the book you wrote called How We Do Harm, which was really a wonderful book. I think it was several years in the making. Would love to hear how you made that. But I do-- while you're talking about your background, speak a little bit about Edward McKnight Brawley and Benjamin. OTIS BRAWLEY: Oh, OK. Benjamin Brawley was my grandfather's brother, and Edward McKnight Brawley was my grandfather's father. They're both ministers in the Methodist Church, the AME Church. Benjamin Brawley was dean of Morehouse College back in the 1920s, and he was the first Brawley to graduate from the University of Chicago. He got a PhD from the University of Chicago back during the 19-teens. And those are just a couple of my relatives. If you go to Morehouse, you'll find that the English building is Benjamin Brawley Hall, and Edward McKnight Brawley was his father and was a free Black back before the Civil War, and a minister before, during, and after. PAT LOEHER: Incredible legacy. Incredible legacy. DAVID JOHNSON: Those were your relatives from the South from the Georgia area? OTIS BRAWLEY: Well, my father grew up in Northwestern Alabama. An area called Leighton, Alabama. It's near Muscle Shoals. So those of us who remember the Beverly Hillbillies. My mother is from the middle of Arkansas. She's from Pine Bluff, Arkansas. And they met in Detroit. They were part of that northern migration in the early 20th century, where a large number of Blacks left the rural South and went up North to get jobs primarily in the industrial North. My father arrived there right after World War II. He served in World War II, got discharged, and went to Detroit. My mother actually went to Detroit really early on during World War II and worked in an airplane factory during the war. Then the two of them met. My father was a janitor at the Veterans Hospital in Detroit, and my mother worked in the cafeteria there. And that's how they met. They had my older sister, who was 8 years older than me, who became an attorney. And my younger sister was a certified public accountant. PAT LOEHER: What a remarkable story for your parents. And tell us a little bit about your journey to become a physician. How did that happen? OTIS BRAWLEY: It was very interesting. In high school, I was very talkative. I was very interested in policy. I did debate. It was very not a sciencey kind of person. In college, I became very interested in Chemistry and for much of College. I was going to go to graduate school in Chemistry. And luckily, when I was in college, I came under the influence of an infectious disease doc named Elliot Kieff. And he and I became very good friends. He was chief of infectious disease at the University of Chicago at that time. And over about two years, Elliott convinced me to drop the Chemistry thing and go to Medical school. And I applied to Medical school late, because I was so late in making that decision. I got into the University of Chicago and stayed there because my support system was there. And then in Medical school came across another gentleman. I've been very fortunate to have good mentorship and good people. They influenced me over the years. John Altman, who was one of the original medical oncologists back in the 1950s when there was arguments about how we should be staging people. Should there be four stages or three stages, and that sort of thing is when John really cut his teeth in Oncology. He became a great lymphoma doc. John took me under his wing while I was in Medical school, and pretty much open the world up to me, and explained to me how the world rotates in Medicine. And that heavily influenced me. Told me to go into Oncology because I still had an interest in Policy. And he said there's going to be a lot of policy in oncology in the future, and the best way to get involved with it is to get your credentials as a medical oncologist. And in many respects, I think in the early 1980s, John was thinking I was going to be chief medical officer of the American Cancer Society, which I obtained in 2007. PAT LOEHER: Wow. Yeah. We want to hear more about that. I just have to throw this in parenthetically that one of the things I did here is that I applied late to Medical school and got into the University of Chicago. I just wanted to know that I applied early, and there was a lesser known school in Chicago that sent me a rejection letter. And not only did they reject me, the last line of it says, good luck in whatever career you decide to go into, meaning that, if you can't get into our school, there's no way you'll be a physician. So I really admire you. DAVID JOHNSON: Yeah. I applied late too and-- PAT LOEHER: Got into Vanderbilt. DAVID JOHNSON: No. No. No, no. I didn't go to Vanderbilt. I only got into accepted to one medical school, and it was late. I was just like my career as a chief. And I was, like, the last person admitted to my class in med school. That's unbelievably interesting. Tell us, was John your influence to go to the NCI? Or what prompted you to choose the NCI for your medical oncology training? OTIS BRAWLEY: Actually, John was very influential in that decision. I told him I wanted to go into medical oncology when I was a resident in Cleveland. And he said, Otis, in his Austrian accent, I have been expecting this phone call. And he then told me where I was going to apply and gave me a list of nine places to apply. He told me I would get an interview at every one of those places. And as I was going place to place, I should rank them one, two, three, four. And so I called them with his ranking. And my first choice was not the National Cancer Institute. At which point he told me, if you go to that place, I will never speak to you again. PAT LOEHER: Oh wow. OTIS BRAWLEY: And I said, but you told me to go there to interview. He said, I wanted you to interview there, but I don't want you to train there. And I said, well, my first choice is the National Cancer Institute. And he said, fine. And a couple of days later, I got a phone call from the National Cancer Institute, and I got hired. And I will also tell you I called John up. And he says, Otis, I have been expecting this phone call. And then he said, now I want you to realize something. There is an old boys network, and your job is to get more Blacks and women into it. That's how you will thank me. PAT LOEHER: Wow. Wow. DAVID JOHNSON: So you were at the NCI at a period of time where many people would say it was the heyday of the NCI. I think it's still the heyday now, but tell us about your experiences there. What was it like? OTIS BRAWLEY: It was fascinating. It was when Vince DeVita was still the director. I was there for the transition. Eli Glatstein was the chair of Radiation Oncology. It was an amazing group of people. Dan Longo was there doing lymphoma. Marc Lippman was still there doing breast. It was just an amazing group of people when I applied, and interviewed, and when I first got there. And there was still a lot of excitement. We were still heavily involved in chemotherapy. Of course, I was up on the 12th and 13th floor building 10. Down on the second and third floor was Dr. Rosenberg doing his immunotherapy work, which of course, has now paid off dramatically. Some of the old monoclonal antibody work that led to a number of wonderful drugs was being started at that time in the mid to late 1980s. And so it was still a very, very exciting time at the National Cancer Institute. And in many respects, we were still on that burst of optimism that started with Nixon's war on cancer in 1971. It was still felt almost 20 years later at the National Cancer Institute. DAVID JOHNSON: And you linked up with an old friend of mine from the old Southeast Cancer City, a gentleman by the name of Barry Kramer? OTIS BRAWLEY: Yes. DAVID JOHNSON: What a wonderful relationship. So how influential was Barry in your involvement? OTIS BRAWLEY: Barry was incredibly influential. As I said, I have been very fortunate that along the way I have come under the influence of some amazing physicians, and I've had amazing mentorship. And that's actually, I think, important for all of us in oncology. Barry and I got to work together for quite a long while. Barry influenced me and literally taught me epidemiology. Got me some major opportunities at the National Cancer Institute and really was influential in promoting me and boosting my career. PAT LOEHER: I want to move you a little bit longer in your career and talk about the ACS and a little bit your experience there, Otis. And then with that, actually, maybe the secondary question is, a commentary on the leaders over the years that you have had-- the aspects of good things about leadership and the poor things. And obviously, you have certainly much to share on that. OTIS BRAWLEY: Yeah. Well, as I devote my career at the National Cancer Institute, I went to the Division of Cancer Prevention and Control. Under Barry, learned a lot of epidemiology, and learned a lot about screening, learned a lot about treatment outcomes, got very involved with some of the disparities or minority health issues. And then I was very fortunate to be detailed to work in the surgeon general's office and work with David Satcher when he was surgeon general. He's the one who started using the words, health disparities. Prior to that, we called it minority health or special populations. He used health disparities. And I was able to use some of my epidemiologic talents to develop some of those arguments using science to show. And actually some of the things that we had to show, believe it or not, was we had to show that equal treatment yields equal outcome amongst equal patients, because a lot of people, especially the politicians we need to deal with, were really hung up. And we still see this to this day that people are hung up that Black biology is different from white biology. Even in breast cancer today I hear that even though I like to point out there are now six states where the Black death rate for breast cancer is the same as the white death rate for breast cancer. And there are 12 states in the United States where white women have a higher risk of death from breast cancer than Black women in Massachusetts. But anyway, we got into this biology thing. And so I was very fortunate again to work for David Satcher and had some exposure to Tuskegee syphilis trial and the president's apology for that. So I was really involved with a number of things. And then the Jesuits still back there-- always think, always be contemplative, always reflect on what you're doing, always question what you're doing. Father Pawlikowski's maxims, which Dick Cheney sort of preferred is a few years later. And that is there are things you know, things you don't know, things you believe. Question what you know more so than anything else. And so that's really how I develop my concerns about orthodox use of Medicine. And using the science and applying it in a very Orthodox way, I started realizing that a lot of the disparities were due to wasted resources with people being non-scientific especially in the era of the 1990s, where everybody was doing prostate cancer screening, and there was not a single trial to show that prostate cancer screening saved lives. Yet all the resources were going into that, and people were literally-- I was able to go to various safety net hospitals and see all the resources being diverted away. People would shut down cervical cancer screening programs to do prostate cancer, which just didn't make sense. So I got very interested in how you practice medicine. Went to the Emory in 2001, because I wanted some practical experience outside of government. And had a wonderful opportunity to go there. Work at Emory. Work at one of the largest safety net hospitals in the country. Learn a little bit about the practical application of Medicine and some of the problems that people at safety net hospitals encounter. Worked with the School of Public Health and folks who did health education to learn how to convey messages. And then I was very fortunate. You know, the American Cancer Society is right down the street from Emory University. And I had met the chief medical officer of the American Cancer Society, Harmon Eyre, back in the 1990s when I was at the National Cancer Institute. And again this sort of mentoring thing comes up again. Harmon called me up one morning and said, why don't we go to lunch? And so we went to one of the student cafeterias at Emory and had lunch. And he essentially said, you know, I'm 67 years old. I've had this job for 20 years. I'm tired of it. Why don't you take it? PAT LOEHER: Wow. OTIS BRAWLEY: And so I applied to be chief medical officer of the American Cancer Society and got to know John Safran, who, at that time, was the CEO, who was a wonderful man with incredible vision. Again, this mentorship thing comes up again. PAT LOEHER: Well, Dave we had a lot of information here. We're going to carry this over. This concludes the first part of our two-part interview with Dr. Brawley. And our next episode will air on October 5. We'll talk a little bit more about Dr. Brawley's life experiences and particularly his work with the American Cancer Society NCI. He's been an incredible individual, and we look forward to finishing up this conversation. Thank you to all our listeners for tuning in to Oncology Et Cetera an ASCO Education Podcast, where we'll talk about anything and everything. If you happen to have an idea for a topic or guest you'd like to see on the show, please email us at education@ASCO.org. Thanks again. And remember Dave has a face for podcast. SPEAKER: Thank you for listening to this week's episode of the ASCO eLearning weekly podcast. To make us part of your weekly routine, click Subscribe. Let us know what you think by leaving a review. For more information, visit the comprehensive e-learning center at elearning.asco.org.

Guitar players and lovers, you're in for a special treat! In my 2nd session with Grammy winning guitarist & composer LAURENCE JUBER, he plays a guitar piece I wrote for him called… “Guitar Piece” - and explains HOW he played it! This is a unique look into the creative process of one of the most gifted players of the last 50 years. He not only talks about his methodology, Laurence also discusses his love of Renaissance guitar and reveals his deep knowledge of guitar history. Get up and dance to his own newest piece, “Grandma's Blue Chicken Pan”. As if that were not enough, the dashing Wings guitarist also talks about the Beatles use of harmony and how he expresses it on the guitar. In this relaxed chat between old friends, you will laugh, cry and be amazed! A masterclass from a true master. Watch! Listen! Learn! Take notes! And please, subscribe to Radio Richard to be notified of Laurence's next show on DADGAD guitar!!! Join this YT channel to get access to special perks: https://www.patreon.com/radiorichard Help Radio RIchard reach 100k subs:

ASMAC MASTERCLASS JOHN ALTMAN & RICHARD NILES  Different Approaches Explained Moderator: Sylvester Rivers (PART 1)   Composer/Arrangers John Altman (James Bond, Rod Stewart, Monty Python) and Richard Niles (Paul McCartney, Ray Charles, Pat Metheny) demonstrate their different approaches and arranging techniques. For this special ASMAC event, they have both arranged short versions of a simple nursery rhyme, Twinkle Twinkle Little Star. This is a unique opportunity to compare and contrast the working methods of two acclaimed artists with 100 years combined experience. Moderator and legendary arranger Sylvester Rivers asks all the right questions. How did they conceive, plan and execute the arrangement? How did they choose instrumentation, meter, groove, harmonic landscape? Why did they make those choices? Don't miss this opportunity to share some musical knowledge, and some laughs, with three arrangers who have helped create the sounds of our time. BONUS: This 2 hour presentation includes Altman's CHASE SCENE from his score to the James Bond film, GOLDENEYE. PLUS, two live performances of Richard Niles' BANDZILLA, at the 2002 Falkirk Festival, featuring singer PAT KANE and multi award winning jazz guitarist JIM MULLEN playing Niles' arrangements of “Luck Be a Lady” (Guys & Dolls) and “Free Man In Paris” (Joni Mitchell).

John Altman – composer, music arranger, orchestrator talks about a selection of his musical highlights. We cover his time on the late 60s/early 70s music scene, work with The Rutles, Monty Python, Van Morrison, George Michael, Rod Stewart, Bjork and more. The post John Altman appeared first on The Strange Brew.

John Altman: Not to be confused with the British actor, this Londoner is among the most prolific and accomplished composers, arrangers, and producers in the history of recorded music. And when he's not scoring films (James Bond), or making hits with George Michael, Monty Python (“Always Look on the Bright Side of Life”), Rod Stewart, Tina Turner and Barry White, Simple Minds, and Bjork, to cite a scant few, Altman blows his sax on the bandstand with the UK's jazz elite. Hosts David C. Gross and Tom Semioli do their best to fit John's remarkable life into one show. Fortunately Altman will soon publish an autobiography – and we'll have him back on air to tell the rest of his story.John Altman Playlist

John Altman: Not to be confused with the British actor, this Londoner is among the most prolific and accomplished composers, arrangers, and producers in the history of recorded music. And when he's not scoring films (James Bond), or making hits with George Michael, Monty Python (“Always Look on the Bright Side of Life”), Rod Stewart, Tina Turner and Barry White, Simple Minds, and Bjork, to cite a scant few, Altman blows his sax on the bandstand with the UK's jazz elite. Hosts David C. Gross and Tom Semioli do their best to fit John's remarkable life into one show. Fortunately Altman will soon publish an autobiography – and we'll have him back on air to tell the rest of his story.John Altman Playlist 

ACTA's Armand Alacbay sits down with John W. Altman -- distinguished entrepreneur, business leader, educator, and veteran trustee at several college universities -- to explore the distinct strengths that trustees should bring to any institutional governing board. Having recently stepped up as ACTA's board chairman, Altman brings a lifetime of experience and insight into helping higher education institutions stay on course and fulfill their mission.

When musicians get together, they tell funny stories about all the ridiculous, amusing, surprising, crazy, psycho things that happen to them – while they're trying to make a living. So here is a new series of interviews, MUSICIAN'S FUNNIES  on Radio Richard where you get to listen in and giggle along to those conversations. Film composer (James Bond, Monty Python), arranger (Tina Turner, Bjork) and jazz saxophonist John Altman has more stories than a barrel of monkeys and an encyclopedic knowledge of musicians and recordings dating back beyond the dawn of mankind! Join us in the funny business! This is killer stuff and you only get this with Radio Richard! LIKE this video! SUBSCRIBE to our social media! DONATE to our PATREON! Pretty Please! YouTube: https://www.youtube.com/user/DRRICHARDNILES?sub_confirmation=1 Podcast: https://radiorichard.podbean.com/ Facebook: https://www.facebook.com/radiorichard2021 Twitter: https://twitter.com/radiorichard3 Patreon: https://www.patreon.com/radiorichard   #johnaltman​ #richardniles​ #radiorichard #musiciansfunnies #musicinterviews​ #comedy #anecdotes​ #saxophonist #jamesbond #montypython #tinaturner #bjork #arranger​ #interviews​ #podcasts​ #music​ #podcasting​ #podbean​ #educational​ “MUSICIAN'S FUNNIES Theme” ©2021Niles Smiles Music (BMI) “Radio Richard Theme ” ©2021Niles Smiles Music (BMI) sung by Free Play Duo

ALL MUSIC LICENCES AND COPYRIGHTS CLEARED BY BBC RADIO 2 IN 2003. I wrote and hosted this 7-part documentary series for BBC R2 in 2003. In Episode 1, I explain what an arranger is and interview arrangers Harold Battiste, Barry Manilow, Nick Ingman, Pee Wee Ellis, John Altman, Bobby Martin, H. B. Barnum, Jimmie Haskell and Jeremy Lubbock. If you don't know them, you'll know the records they arranged for Aretha, James Brown, Monty Python, Simon and Garfunkel, Dr. John and Michael Jackson.  The series served as the basis for my book The Invisible Artist. For music lovers and students, this series is the mother lode. A lot more incredible content in the next 6 episodes. Don't miss them! Subscribe to my podcast here. Let me know what you think! Radio Richard Theme ©2021 Niles Smiles Music (BMI) sung by Free Play Duo

This week we have John Altman back on the show to discuss their new project on Blood Trailing and recovery of big game animals   VORTEX MERCHANDISE SAVE 20% - https://bit.ly/2KemVsx​ - BOWGA20 Trophy Line Tree Saddles SAVE 10%- https://bit.ly/3nN4aKu​ - BOWGAHUNTINGTL10 Wild Pursuit Wellness SAVE 20% - https://bit.ly/3bFPlqW​ - BOWGA   Other Sponsor Links: www.firstlite.com www.huntwise.com https://grillagrills.com www.bivouacbowco.com

Charlie talks about going out on Yard for exercise, explains where Broadmarsh can be bought and talks about his new record. He then asks if I can get in touch with John Altman, talks about Quadrophenia and To Be Someone. Then we hear Charlie's message to 'John Altman and John Altman's message in response to Charlie. Classic Charlie! New documentary streaming now at www.brideofbronson.co.uk

Retiring ASCO Chief Medical Officer Dr. Richard L Schilsky gives a far-reaching interview with ASCO in Action podcast host ASCO CEO Dr. Clifford A. Hudis, who examines Dr. Schilsky’s trailblazing medical career, his leadership in ASCO and indelible mark on its research enterprise, and what he sees for the future of oncology. ASCO’s first-ever Chief Medical Officer even offers some friendly advice for Dr Julie Gralow, who starts as ASCO’s next CMO on February 15, 2021. In a touching tribute, Dr. Hudis also shares what Dr. Schilsky’s friendship and mentorship has meant to him personally, and suggests that Rich will still be supporting ASCO on critical priorities moving forward. Don’t miss this exchange with one of oncology’s greats! Transcript DISCLAIMER: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. CLIFFORD HUDIS: Welcome to this ASCO in Action podcast brought to you by the ASCO Podcast Network, a collection of nine programs covering a range of educational and scientific content and offering enriching insights into the world of cancer care. You can find all of the shows, including this one, at podcast.asco.org. The ASCO in Action podcast is a series where we explore the policy and practice issues that impact oncologists, the entire cancer care delivery team, and the individuals we care for-- people with cancer. My name is Dr. Clifford Hudis. And I'm the CEO of ASCO and the host of the ASCO in Action podcast series. For today's podcast, I am especially pleased to have as my guest my friend, colleague, and mentor Dr. Richard Schilsky, ASCO's chief medical officer. Now, I am sure that many of our listeners have already heard that Dr. Schilsky will be leaving ASCO in February of 2021, retiring. However, I want to reassure everybody that even in retirement, he will continue to make contributions and provide leadership to all of us. And his illustrious and path-blazing career in oncology spanning more than four decades is not quite over thankfully. Rich is ASCO's first chief medical officer. And as such, he has made a truly indelible mark on all of us. He started with a proverbial blank piece of paper. The position had no precedent. It had no budget. It had no staff. But now after just eight years in the role, he has helped make the CMO a critically important position at the society. And I have to say that success is more than anything due to Rich's vision and his leadership. And that's some of what we'll be talking about today. So Rich, thank you very much for joining me today for what I hope is going to be a great casual but informative conversation about your amazing career, your unique role at ASCO, and maybe most importantly in the end what you see for the future of oncology not just in the United States, but around the world. Thanks for coming on, Rich. RICHARD SCHILSKY: Thanks, Cliff. It's great to be here today. CLIFFORD HUDIS: So with that, let's just dive right in and start at the very beginning. Rich, tell everybody why you decided to become an oncologist and maybe share a little bit about what those early days looked like for you and, in that context, what it was like to have cancer at the beginning of your career. RICHARD SCHILSKY: Well, I knew from an early age that I wanted to be a doctor. And in fact, I had written a little essay when I was in sixth grade as a homework assignment called My Ambition. And my mother had tucked that away in a scrapbook. And I found it a number of years ago. And on rereading it, it was quite amazing to me to see what I was thinking about even then. Because I said not only did I want to be a doctor, but I didn't think that was enough, that I wanted to be a medical researcher because I wanted to discover new information that would help people heal from whatever their diseases might be. And so it was never really any doubt in my mind that I would be a physician. I went to medical school at the University of Chicago. But I was living in New York City at the time having grown up in Manhattan. And the only year we had off in medical school, the only time we had off in medical school, was the summer between the end of the first year and the beginning of the second year. So during that time, I went back to Manhattan. And I was able to get a fellowship from the American College of Radiology that allowed me to essentially hang out in the radiation therapy department at New York University Medical Center, which was within walking distance of where I grew up. And so I would go over there every day. And I was taken under the wing of a young radiation oncologist. And of course, I wasn't really qualified to do anything at that point except to follow him around, talk and listen to the patients. But that turned out to be a really formative experience for me because we saw the whole gamut of cancer. We saw head and neck cancers. We saw lung cancer. We saw patients with breast cancer and prostate cancer. And in those years-- this is the early 1970s-- many of these patients have fairly locally far advanced disease and were quite debilitated by it. But listening to their stories, hearing about their hopes and their struggles, really demonstrated to me the human side of cancer. So I went back to school and thought about this in the context of my own personal experience, which dated back to when I was in college when my mother's mother, my maternal grandmother, was diagnosed with breast cancer. This was 1968. And as you well know, there were very few therapies available for breast cancer in the late 1960s, mostly hormone therapies. And my grandmother had the treatment that was considered standard of care at that time, which was extended radical mastectomy followed by chest wall radiation. And some years after that first mastectomy, she had a breast cancer that developed in the opposite breast and had a second extended radical mastectomy and chest wall radiation. And these were very traumatic and disfiguring procedures for her to go through. Anyway, long story short is after another few years, she developed bone metastases and then brain metastases. And there was really very little that could be done for her other than hormone therapies. And having observed her go through that illness and realizing how limited our treatment options were and then having the experience after my first year in medical school pretty well cemented for me that I wanted to be an oncologist. I thought actually about being a radiation oncologist. But then I did my internal medicine rotation in medical school, fell in love with internal medicine. And that sort of put me on the path to be a medical oncologist. The clinical challenge of caring for cancer patients, the emotional attachment to those patients, and, of course, even then, the unfolding biology of cancer was so intellectually captivating that I actually applied for oncology fellowship when I was a senior medical student. So even before going off to do my medical residency, I had already been accepted as a clinical associate at the National Cancer Institute to start two years hence. And that's how I became an oncologist. CLIFFORD HUDIS: So it's so interesting. Because, of course, the story I'm sure for many people interested not just in oncology, but even medical education, there are little things that don't happen nowadays that happened with you like that last little vignette about the early acceptance into an advanced training program before your fellowship among other things. Can you remind us about the timeline? Because I think one of the things that many of our listeners often can lose sight of is just how new oncology really is as a specialty. ASCO itself founded in 1964. And the first medical oncology boards were mid-'70s, right? So you were in med school just before that second landmark, right? RICHARD SCHILSKY: That's right. I graduated from medical school in 1975. I started my oncology fellowship in 1977. And I got board-certified in medical oncology and joined ASCO in 1980. And so that was the time frame at that point. CLIFFORD HUDIS: So the internal medicine was actually, if I heard you right, just two years, not the now traditional four. RICHARD SCHILSKY: Yeah. I was a short tracker. I did only two years of internal medicine training rather than three. I did my training at Parkland Hospital and University of Texas Southwestern in Dallas with at that time a legendary chair of medicine, Don Seldin, who I had to get permission from him to leave the program prior to completing the third year of residency because I had already been accepted into fellowship at NCI. And he, Seldin, who was a brilliant chairman and a brilliant nephrologist, was not at all interested in cancer. And it took a bit of-- I was going to say arm twisting, but it really took bleeding on my part to get him to agree to allow me to leave the residency program to go to the NCI. But he eventually agreed. And in those years, the first-year clinical fellowship at the NCI was like being an intern all over again. There were about 15 of us. We were on call overnight in the clinical center once every two weeks. We cared for all of our inpatients as well as had a cadre of outpatients. We did all of our own procedures. We had no intensive care unit. So patients who were sick enough to require ventilator support, we cared on the floor in the inpatient service on our own with guidance from senior oncologists. It was a bit different from the way it is now. But, of course, it was fantastic on-the-job training because we just learned a ton and had to learn it very quickly. CLIFFORD HUDIS: So that's actually a great segue to the advances because there was a lot to learn then. But, wow, there's a lot more to learn, I think, now. And I have real sympathy for trainees and younger oncologists for the breadth of what they need to learn. Again, just testing your memory, but platinum came along pretty much in the mid-'70s as well, right? That was a pivotal expansion of the armamentarium for us. So what do you see-- when you summarize progress in cancer research and care over these decades, what do you think are the most pivotal or revolutionary milestones that you identify over the span of your career? RICHARD SCHILSKY: Yeah. It's really interesting to think about it historically. There were the early years of discovery in oncology from the 1950s to the 1970s when we really had the introduction of the first chemotherapy drugs and the miraculous observation that people with advanced cancer could actually obtain a remission and, in some cases, a complete remission with chemotherapy and combination chemotherapy in particular. And so that was the formative years of oncology as a medical specialty and really proof of concept that cancer could be controlled with drugs. When we got into the 1980s, the 1980s in many respects were the doldrums of progress in clinical oncology. There really was not a lot of innovation in the clinic. But what was happening and what was invisible to many of us, of course, was that was the decade of discovery of the fundamental biology of cancer. That's when oncogenes were discovered, when tumor suppressor genes were discovered, when it became clear that cancer was really a genetic disease. And that is what transformed the field and put us on the path to targeted therapy and precision medicine as we think of it today. So I think that clearly understanding the biology of cancer as we do now and all that it took to lead us to that point, which was a combination of understanding biology, developing appropriate technology that would, for example, enable the sequencing of the human genome and then the cancer genome. And the other formative technology in my opinion that really changed the way we care for cancer patients was the introduction of CT scanning. When I was still a fellow at the NCI, we did not have a CT scanner. If we needed to get detailed imaging of a patient, we did tomography. And if you remember what tomograms looked like, they were really blurry images that you could get some depth perception about what was going on in the patient's chest or abdomen. But they really weren't very precise. When CT scanning came along, it really revolutionized our ability to evaluate patients, assess the extent of disease, stage them in a much more precise way, which then allowed for better patient selection for curative surgery, better radiation therapy planning. So we don't often point to imaging advances as some of the transformative things that paved the way in oncology, but I think imaging is really overlooked to some extent. So I think the technology advances, the biological advances, are the things that really allowed the field to move forward very quickly. And by the time we got into the mid-1990s, we were beginning to see the introduction of the targeted therapies that have now become commonplace today. And then it was around 2000, I think, that we saw the introduction of Gleevec. And I'm reminded always about an editorial written by Dan Longo in The New England Journal a few years ago. And Dan and I were fellows together. We worked side by side on the wards at the clinical center and became very good friends. And Dan in his role as a deputy editor of The New England Journal wrote an editorial a few years ago that was titled "Gleevec Changed Everything." And Gleevec did change everything. It changed our entire perception of what were the drivers of cancer and how we might be able to control cancer very effectively and potentially put it into long-term remission. Now, of course, we know now that the whole Gleevec story is more of an exception than a rule in targeted therapy. And, of course, we know that tumors become resistant to targeted therapies. But we couldn't have known any of this back in the early years of oncology because we had no real insight into what caused cancer to grow or progress. And the notion of drug resistance, while we realized that it occurred, we had no idea what the mechanisms were. So it's such a different landscape now than what it used to be. It's quite remarkable. CLIFFORD HUDIS: So as you tell the story, there's, of course, a lot of focus on technology, whether it's biology and understanding the key features of malignancy or imaging or more. But what I also note in your story and I want to come back to is the people. And I can't help but reflect on where we are in this moment of the COVID-19 pandemic. Yes, we've moved to telemedicine. Everything can be accomplished via technology. And, yet, the human touch is so important. When we think about being in the room with people, when we think about face to face from the context of career development and your own career, you touched on Dr. Seldin, I think, already from the perspective of internal medicine training. But are there are other mentors or important shapers of your career that you think we should know about? RICHARD SCHILSKY: Well, probably, the most influential person early in my career in medical school was John Altman. John, you may know, was the inaugural director of the University of Chicago's NCI-designated Cancer Center, which was one of the very first NCI-designated cancer centers in 1973 after the National Cancer Act of 1971 created the cancer centers program. And John, who was a leading oncologist studying Hodgkin and non-Hodgkin's lymphoma, was a faculty member there. He was the director of our cancer center as I said. He took me under his wing even when I was in medical school and served as a real role model and mentor to me. When I was in my internal medicine training as I mentioned earlier, Don Seldin, the chair of medicine, was never particularly interested in oncology. So, to some extent, I didn't have-- I had great internal medicine training. But I did not have good mentorship in oncology. When I got to the NCI, then my whole world really opened up. And the two pivotal people there in my career were Bob Young, who was chief of the medicine branch and was my clinical mentor and remains a mentor and friend to this day, and then, of course, Bruce Chabner, who was the chief of the clinical pharmacology branch. And in my second year of fellowship when we all went into the laboratory, I went into Bruce's lab. And that's where I really got interested in the mechanism of action of anti-cancer drugs and ultimately in drug development and early phase clinical trials. And both Bob and Bruce remain very close to me even today. CLIFFORD HUDIS: So I'm concerned about time on our call today on our discussion. Because we could obviously fill lots of hours on all of these remarkable experiences and amazing people you worked with. But I'm going to ask that we fast forward a little bit. You and I share, I think, passion and love for ASCO. So I think that it's reasonable for us to focus a little bit on that for the time we have left here. You didn't start out obviously as chief medical officer at ASCO. But you were a really active ASCO volunteer and leader. Maybe tell us a little bit about some of the ASCO volunteer roles that you engaged in and what that meant to you at the time and how that led to this role. RICHARD SCHILSKY: Well, I'll be brief. I joined ASCO in 1980 at the first moment that I was eligible to join ASCO. I had attended my first ASCO meeting the year before, 1979, when I was still in my fellowship training. And it was clear to me even then when the whole annual meeting was about 2,500 people in two ballrooms in a hotel in New Orleans that that was a community of scholars and physicians that I wanted to be a part of. And so, over the years, I did what people do even today. I volunteered to participate in whatever ASCO activity I could get involved with. Over the years-- I think I counted it up not too long ago-- I think I served or chaired 10 different ASCO committees, more often serving as a member, but in a number of those committees also serving as the chair over many years. And as I became more deeply involved in ASCO and saw other opportunities to engage, I had the opportunity to run for election to the board and was-- after a couple of tries was elected to serve on the board and then eventually elected to serve as ASCO president in 2008-2009. But the attraction of ASCO in many ways was a community of diverse but, in many ways, like-minded people, people who had similar passion and drive and focus. But I think what you get at ASCO in many ways is the wonderful diversity of our field. If you work in a single institution for much of your career as I did and as you did, you get to know that institution pretty well. You get to know its perspectives and its biases and its strengths and its weaknesses. But there's a whole world of oncology out there. And you can get exposed to that at ASCO because you meet and work with colleagues from every clinical setting, every research setting, people who have remarkable skills and interests and passions. And it's just a wonderful environment to help develop your career. So I consider myself to be extremely fortunate to have had the journey in ASCO that I've had culminating, of course, with ultimately my coming on the staff as ASCO's first chief medical officer. CLIFFORD HUDIS: We often joke about that blank sheet of paper. But in retrospect, it's very obvious that you had built up that collection of LEGO blocks, and then you assembled them all into the ASCO Research Enterprise, a name you gave it. And it really, in retrospect, builds, I think, very cleanly upon all of your prior experience, but also the vision that you developed based on that experience for how research should be conducted. Can you maybe share with everybody the scope and vision for the ASCO Research Enterprise, what the intent was, and where you see it going, and what it includes today? RICHARD SCHILSKY: Sure. I won't claim that I came to ASCO with the whole thing fully developed in my mind. As you said, when I came, I literally did have a blank slate. Allen Lichter, who hired me, said, come on board and help me make ASCO better. And so I, in a sense, reverted to what I knew best how to do, which was clinical research. And having in my career been a cancer center director, a hem-onc division chief, a cooperative group chair, I had a lot of experience to draw on. And it was obvious to me that ASCO was fundamentally an organization that took in information from various sources, evaluated it, vetted it, collated it, and then disseminated it through our various channels, most notably our meetings and our journals. But ASCO itself did not contribute to the research enterprise. And that seemed to me to be a lost opportunity. We knew that ASCO had lots of data assets that could be of interest to our members and to the broader cancer community. But they were scattered all around the organization and not particularly well annotated or organized. So we began to collate those. And they are now available to ASCO members on the ASCO data library. I recognized that we did not have an organized unit in ASCO to support or facilitate or conduct research. So, in 2017, we formed the Center for Research and Analytics and brought together staff who were already working at ASCO but scattered in different departments but all people who had an interest in clinical research or research policy and brought them into this new unit, which has really become the focal point for research work at ASCO. We recognized that ASCO members for many years were interested in surveying their colleagues, surveying other ASCO members, to help advance research questions. But ASCO actually had a policy that prohibited that. So that never really made good sense to me. It seemed like a lost opportunity. And we were able to create a program and have the ASCO board approve it whereby any ASCO member could opt in to participate in what we now call the Research Survey Pool. And in doing so, they are essentially agreeing to participate in research surveys conducted by their colleagues. So that program is now up and running. There are, I think, eight surveys that have been completed or are currently in the field. And this is now a service that ASCO provides through CENTRA to its members to enable them to survey their colleagues for research purposes. Most importantly, I think we saw an opportunity back in 2014 or 2015 to begin to learn from what our colleagues were doing in clinical practice as they began to deploy precision medicine. And there was a lot of genomic profiling that was going on at that time. It was revealing actionable alterations in roughly 30% or so of the tumors that were profiled. But there was a lot of difficulty in doctors and patients obtaining the drugs that were thought to be appropriate to treat the cancer at that particular time because most of those drugs would have to be prescribed off label. And there was not a sufficient evidence base to get them reimbursed. And, moreover, even if they could be reimbursed, there was no organized way to collect the patient outcomes and learn from their experiences. So that led to us developing ASCO's first prospective clinical trial, TAPUR, which really solves both of those problems. Through the participation of the eight pharmaceutical companies that are engaged with us in the study, we are providing-- at one point, it was up to 19 different treatments free of charge to patients. These are all marketed drugs but used outside of their FDA-approved indications. And we were collecting data on the patients, the genomic profile of cancer, the treatment they received, and their outcomes in a highly organized way. And so now this is a study that we launched in 2016. We're now almost to 2021. We have more than 3,000 patients who have been registered on the study, meaning consented to participate, more than 2,000 who have been treated on the study. And we are churning out results as quickly as we can about which drugs are used or not useful in the off-label setting for patients whose tumors have a specific genomic profile. So we built all this infrastructure. And having this in place has also then allowed us to respond rapidly to unmet needs. So when the COVID-19 pandemic overwhelmed all of us, and when our members were looking for information about what was the impact of COVID-19 on their patients, one of the things we were able to do because we had CENTRA, because we had a skilled staff and an infrastructure, was to very quickly stand up the ASCO COVID-19 registry, which we launched in April of this year. And there are now about 1,000 patients who've enrolled in the registry from around 60 practices that are participating. And we will follow these patients now longitudinally and learn from their experiences what has been the impact of the COVID-19 illness on them and their outcomes, how has it disrupted their cancer care, and ultimately how that impacts their overall cancer treatment outcomes. So as I now contemplate leaving ASCO after eight years having started with a blank slate, I'm very proud of the fact that I think I'm leaving us with a remarkable infrastructure. We now have a clinical trials network of 124 sites around the country participating in TAPUR that we never had before. We have through the work of CancerLinQ a real-world evidence data generator that is beginning to churn out valuable insights. We have a capacity to survey ASCO members for research purposes. We have an ability to stand up prospective observational registries to gather information longitudinally about patients and their outcomes. We have a core facility in CENTRA with highly skilled data analysts and statisticians that can support these various research activities. So ASCO is now primed, I think, to really contribute in a very meaningful way to the gaps in knowledge that will forever exist in oncology just because of the complexity of all the diseases we call cancer. And that's what I mean by the ASCO Research Enterprise. It is in fact remarkable and, I think, powerful enterprise if we continue to use it effectively. CLIFFORD HUDIS: Well, that's an interesting segue to my next thought, which is really about what comes next. I'll talk about you. But let's start with ASCO first. Your successor, Dr. Julie Gralow, obviously has been announced publicly. She's an accomplished clinician and researcher. She has a known recognized passion for patients, patient advocacy, clinical research through her leadership at SWOG but also health care equity and global oncology. So from your perspective, having created all of these assets and resources, what advice would you give Dr. Gralow publicly on how to make the position hers, what to take us to next? And I do want to acknowledge for everybody listening that the hints I've been making up until now are that Rich has agreed that he will continue to contribute as a leader to TAPUR for the short term, at least, at least the next year helping Julie get fully oriented to this program and others. So what will your advice be to Julie? RICHARD SCHILSKY: That's a great question. She's a great selection. And congratulations on hiring her. I think there are two key issues, I think, maybe three. One is to have a broad scope and cast a wide net. Oncology care and cancer research and cancer biology are incredibly complicated and nuanced and broad in scope. And although Julie is an accomplished breast cancer clinician and researcher, in this role at ASCO, you have to be very broad. You have to understand all of cancer care, all of cancer research, all of policy and advocacy not as an expert in necessarily in any one aspect of ASCO's work, but you have to understand the impact of all of those things on cancer care providers and on cancer patients. And it's important to always be looking to the future. The future is going to be here before you know it. And we as a professional society have to prepare our members for that future. So that leads me to the second point, which is listen to the members. The members are the people on the front lines who are delivering care to patients every day. And, fundamentally, ASCO's job is to be sure that our members have all the tools and knowledge and resources that they need to deliver the highest quality care to patients every day. So listening to what they need, what their struggles are, what their burdens are, is extremely important. And then the third thing I would recommend to her is that she get to know the staff and colleagues that she'll be working with. ASCO has a remarkably accomplished, skilled, motivated, passionate staff, many of whom have been with the organization for years, if not decades, who understand what ASCO can and cannot do and who understand what our members need. And she will be well advised to spend a good portion of her first few months on the job just listening and learning from her colleagues. CLIFFORD HUDIS: That's always good advice for anybody making a big career move. But, of course, the wisdom you bring to it is palpable and much appreciated. And I'm sure Julie will be taking your advice. And, by the way, so will I continue to do that even after you make your move. So speaking of your retirement, can you share with us a little bit about what it's actually going to look like for you? Is it about family? Or are you still going to have some professional engagement? Again, I suggest that there might be some already, but maybe you could expand on it. RICHARD SCHILSKY: Yeah. I'm still fully focused on my work at ASCO. And, of course, as you know, when I wake up on February 15, I will no longer be ASCO's chief medical officer. And it's going to be a bit of a rude awakening. Fortunately, I will be able to continue my engagement with ASCO through the TAPUR study as you mentioned. I will, of course, forever be at ASCO member and a donor to Conquer Cancer and be willing to serve the society in any way. I have a number of activities that I've been involved with even throughout my time at ASCO. Not-for-profit boards, for example-- I'm on the board of directors of Friends of Cancer Research. I'm on the board of directors for the Reagan-Udall Foundation for FDA. I plan to continue with those activities as long as they'll have me. I've been serving the last few years on the board also of the EORTC, the large European cooperative clinical research group. And I expect to continue in that role. Beyond that, I will see what opportunities come my way. I think one of the things about retirement if you will that I'm looking forward to is the opportunity to pick and choose what to work on based on what interests me without having the burdens of having a full-time job. On the personal front, of course, we're all looking forward to crawling out from the pandemic. I've basically been locked in my home outside Chicago since March. And I'm looking forward to getting back out to a little bit of a social life. As you know, I have two grown daughters and now three grandchildren, two of whom are in Atlanta, one of whom is near by us in the Chicago area. So looking forward to spending time with them as well. So it will be a change for me to be sure after working as hard as-- I feel like I've worked for really now 45 years since I graduated from medical school. But I also feel like I'm not quite done yet and that I still have ways in which I can contribute. I just feel like at this point, maybe it's time for me to choose how I want to make those contributions and spend a little bit more time doing some other things. CLIFFORD HUDIS: Well, both you and my predecessor, Allen Lichter, are modeling something, have modeled something, that I think is not often discussed but can be very important. For people and for institutions, change is not a bad thing. And setting the expectation that you will pour your heart and soul into something but not necessarily do it alone or forever and not prevent others from taking that role at some point, that's a really-- I think it's a selfless kind of sacrifice in a way. Because, of course, you could stay and do what you're doing for longer. But as you and I have discussed, there is a value for all of us collectively in having fresh eyes and new people take organizations in a new direction. That's how I ended up here frankly. And I think that's the kind of opportunity you're creating right now, something that should be celebrated in my opinion. RICHARD SCHILSKY: Well, thanks. And I couldn't agree more. When I look back at the arc of my career and having all the different kinds of leadership roles that I've had, I basically have made a job change every 8 to 10 years. I was the director of our cancer center for nearly 10 years. I was associate dean for clinical research at the University of Chicago for eight years, another position that I created from a blank slate at that institution. The exception was serving 15 years as a CALGB group chair. But that was a position I really loved and enjoyed and felt like at the end of the first 10 I hadn't quite accomplished everything I wanted to accomplish. But the point is that I think it is both necessary for organizations to have regular leadership change. And it's also refreshing for us as individuals. There gets to a point where you feel like you can do your job in your sleep. And I actually think that's a good time to make a change. Because if that's the way you feel, you're not being sufficiently challenged. And you're probably not being sufficiently creative. And so it's a good time to move on and refresh your own activities and give your organization a chance to bring in someone to hopefully build on whatever you've created and bring it to the next level. CLIFFORD HUDIS: Well, I agree with all that, although I think your comment there about doing the job in your sleep would not apply because I'm pretty confident that the environment and opportunities have continued to evolve in a way that has made it interesting from beginning to end. But you don't have to rebut me on that. I just want to thank you very, very much, Rich. As we set up this podcast, I expected that we would have a really fun and enlightening conversation. And, of course, you did not disappoint. We could talk for much, much longer if we only had the time. On a personal note to you and for the benefit of our listeners, I want to share that Rich has been for me a remarkable friend and mentor and colleague. I first met Rich at the very beginning of my career when my mentor, Larry Norton, pushed me out from Memorial into the larger world. And he did that first and primarily through ASCO and the Cancer and Leukemia Group. Those are really the two places where I was exposed to the world. And through the CALGB, Rich really began to offer me and others, many others, opportunities that shaped careers plural, mine and others. So when I got to ASCO as CEO, Rich was there. And I knew I could always depend on you to be clearheaded, intellectually precise, constructive, visionary. And the thing about you, Rich, is that you never would say yes to anything unless you knew for sure you could do it and indeed, I think, how you could do it. I always share this story which your staff at CENTRA pointed out to me. And I have to admit that I hadn't picked it up myself. But in all the years of now working down the hall from Rich, probably hundreds and hundreds of hours of meetings, he never has taken a note in front of me. And, yet, everything we talk about, every action item we conclude to pursue, they all get done. So I don't know, Rich. You have a remarkable way of organizing your thoughts and your plans, keeping it together, and getting things done. And I'm going to miss that tremendously in the years ahead. So, Rich, I want to say congratulations. Congratulations on reaching this really important milestone in your life. Thank you on behalf of ASCO and the broader oncology community and the patients we care for and their families for making the world a better place. And just as a small thing, thank you for joining me today for this ASCO in Action podcast. RICHARD SCHILSKY: Thank you, Cliff. It's been great. CLIFFORD HUDIS: And, for all of you, if you enjoyed what you heard today, don't forget to give us a rating or a review on Apple Podcasts or wherever you listen. And, while you're there, be sure to subscribe so you never miss an episode. The ASCO in Action podcast is just one of ASCO's many podcasts. You can find all of the shows at podcast.asco.org. Until next time, thank you for listening to this ASCO in Action podcast.

Steve Wraith Interviews John Altman about his role as Nick Cotton in Eastenders and his new album. recorded during lockdown in 2020. Never Too Late To Rock And Roll is the debut album by actor and musician Johnny Altman released on Nov 20th via NUB Music / The Orchard. The lead single from the album is Hallucinating You released Oct 16. https://www.youtube.com/watch?v=YUktq...

My guest today is none other than the legend that is John Altman. John has been described as a musician's musician and as musical royalty. He's won BAFTAs and EMMYs, been given a Lifetime Achievement Award for his work in the film industry AND an Honorary Doctorate of Music from the University of Sussex in the UK. I could genuinely spend the length of this episode just listing the projects this one guy has worked on, ranging from TV Shows to films, arranging the music for commercials to performing on hit records for some of the biggest names in popular and contemporary music - it's mind boggling how prolific John has been throughout his career and he's showing no signs of slowing down. John is also an Ambassador for Alopecia UK, the main British charity that work to improve the lives of those affected by alopecia - alopecia.org.uk Photo of John Altman © Danny Clifford - dannyclifford.com -- This episode is sponsored by Northern Powerhouse Media. To find out more about Northern Powerhouse Media's extensive range of products, go to npmedia.co.uk. Use promo code SODSPOD for a 50% introductory discount on your first order. If you'd like to support Sod's Law you can become a Sod's Law patron at patreon.com/sodspod from as little as £1 /$1 a month - there are different tiers including ad-free episodes, giveaways and more!

In this interview we talk to John Altman about his experiences in the world of film scores. For a full track listing of the music played in this podcast please visit www.mrdemillefm.com (http://mrdemillefm.com/tracklists/?podcast=john-altman) Please email us with comments, suggestions etc. The email address is info@mrdemillefm.com (mailto:info@mrdemillefm.com)

This week we sit down with John Altman, hunting master, to discuss his approach to hunting big old Coastal Maine bucks. We talk about what it’s like to hunt in Maine, filming your hunts and how John went about killing Bigfoot. John was a gracious guest and took the time to answer all of our questions about how he scouts and prepares for killing big bucks. We also got to talk about John’s most recent film series, Seabucks. Check it out!   Sponsor Links: https://vortexoptics.com www.firstlite.com www.seekoutside.com www.huntwise.com https://grillagrills.com www.bivouacbowco.com www.trophyline.com

Today on the show I'm joined by John Altman, of the new whitetail show Sea Bucks, to discuss his unique tactics for hunting mature bucks across the islands and big woods of the Northeast. Topics discussed: Why island hunting is a sneaky effective way to hunt mature bucks Tips for accessing islands to hunt deer How wind and available space impact how you hunt islands How John killed a 12+ year old island buck Annual patterns for Northeast deer Scouting and locating mature bucks in the big woods of the Northeast Dissecting stand set-ups for big woods deer How do calling and rattling work in the big woods Tracking deer on foot Connect with Mark Kenyon and MeatEater Mark Kenyon  on Instagram , Twitter , and Facebook MeatEater on Instagram, Facebook, Twitter, and Youtube Shop MeatEater Merch

Today on the show I'm joined by John Altman, of the new whitetail show Sea Bucks, to discuss his unique tactics for hunting mature bucks across the islands and big woods of the Northeast. Topics discussed: Why island hunting is a sneaky effective way to hunt mature bucks Tips for accessing islands to hunt deer How wind and available space impact how you hunt islands How John killed a 12+ year old island buck Annual patterns for Northeast deer Scouting and locating mature bucks in the big woods of the Northeast Dissecting stand set-ups for big woods deer How do calling and rattling work in the big woods Tracking deer on foot Connect with Mark Kenyon and MeatEater Mark Kenyon  on Instagram , Twitter , and Facebook MeatEater on Instagram, Facebook, Twitter, and Youtube Shop MeatEater Merch

Dr. Hayes interviews Dr. Muggia about his time at NCI. TRANSCRIPT: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care, and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. [MUSIC PLAYING] Welcome to JCO's Cancer Stories, the Art of Oncology, brought to you by the ASCO Podcast Network-- a collection of nine programs carrying a range of educational and scientific content, and offering enriching insight into the role of cancer care. You can find all of the shows, including this one, at podcast.asco.org. [MUSIC PLAYING] Hi, and welcome to Cancer Stories. I'm Dr. Daniel Hayes. I'm the medical oncologist, and I'm also a researcher at the University of Michigan local cancer center. And I'm the past president of the American Society of Clinical Oncology. I am truly privileged to be your host for a series of podcast interviews with the founders of our field. Over the last 40 years, I've really been fortunate. I've been trained, mentored, and I've been inspired by many of these pioneers. It's my hope that through these conversations, we can all be equally inspired and gain an appreciation of the courage and the vision, and frankly, the scientific understanding that led these men and women to establish the field of clinical cancer care over the last 70 years. I hope that by understanding how we got to the present and what we now consider normal in oncology, we can also imagine and work together towards a better future for our patients and their families during and after cancer treatment. Today, I'm pleased to have, as my guests on this podcast, Dr. Franco Muggia. He's generally considered one of the pioneers of new drug development oncology going all the way back to the 1960s. Dr. Muggia is currently a professor of medicine and co-chair of the GYN Cancer Working Group at NYU, and a member of their breast cancer program. He was born in Turin, Italy before the war. But when he was about three years old, his family fled to Ecuador to escape Mussolini's fascism. After growing up there at the age of 18, he moved to the United States in Danbury, Connecticut, to finish high school. And then he received his undergraduate degree in biophysics from Yale in 1957. In 1964, he became a US citizen. But he's remained true to his roots and has been very involved with both US/Italian cancer collaborations and mentorship, and also with South America for decades. He went to medical school at Cornell, followed by an internship at Bellevue in New York City, and a residency at Hartford Hospital in Connecticut. He completed a fellowship in medical oncology hospital in 1964-1967. And we're going to talk about that, Franco. And since he's had a number of important academic positions at Einstein, the NCI, University of Southern California, and New York University on two different occasions, and that's where he still practices. He's been involved in the development of clinical trials of hundreds of new drugs through the years, perhaps most notably, cisplatinum. In regards to ASCO, he served on our cancer education committee and on the editorial board of JCO. In fact, I understand you were the first editor of the Spanish edition of JCO. Correct. Correct. And perhaps more importantly, he's been a direct, and an indirect, mentor of hundreds of medical oncologists of the decades at that many institutions he's served, including myself, frankly, in my association with his good friend, George Canellos. Dr. Muggia, welcome to our program. Thank you very much, Dan. And I would just say, just a comment on the citizenship. So once I became a citizen, I actually became eligible for the draft. And that was the main reason why I ended up at the National Cancer Institute. So it had a-- it was a great effect on my career, that I actually volunteered for the Public Health Service in 1969. Because Lyndon Johnson changed the rules for physicians. And if you hadn't served, you had to serve up to age 35. So I decided I should join, not head to Vietnam like the rest of my classmates-- like many of my classmates from Cornell. And it really was a career change for me. Actually, that's a recurring theme in my podcast series. I have interviewed several people at the NCI in the mid to late '60s and early '70s sort of pejoratively, but actually not. You all became known-- as you've put in some of the things you've written-- as the yellow berets. Right. But in fact, it's really, I think, fundamentally changing-- NIH in general, and especially the NCI. We'll talk about that more later. I know your father was a pediatrician. Leaving Europe in the 1930s must have been extraordinarily painful for him and your family. Can you tell us more about that, and getting to Ecuador? Well, he was-- he never joined the fascist party. In fact, he was best friends with the socialists that remained at that time. Mussolini was brutal. He wanted everybody to become a fascist. And anybody who served at the University lost their jobs. He was in a bit of hot water as well. So that, plus the racial laws, which made Jews not be citizens, led to a big decision in the family. It was a phone call, whether we wanted to join an enterprise-- whether he wanted to join an enterprise in Quito, Ecuador in a pharmaceutical company. And my mother said, I don't know where the place is, but let's go. So that's how it happened. So in a matter of a few weeks, we were gone. And I was three years old. So how did you end up getting to Connecticut? Well, that was-- the American School of Quito, which I was a founding member in kindergarten. There was this person who became Ecuadorian, who was actually born in New York because his father was a consult here in the early 1900s, Galo Plaza Lasso. He decided, hey, we need a school-- a private school that-- non-religious, that competes with the German school that's there. We're going to call it the American School of Quito. So I was a founding kindergarten pupil, and ended up going right through to graduation with my class, except that the last year, I was an exchange student in Danbury, Connecticut. Because our principal, who was a champion swimmer-- Ashby Harper-- and John Verdery, who was at the Wooster School principal, they were together in Princeton. And they decided to make this exchange program, which ended when-- I was the last one, actually, of six years. My brother, he was there three years before. But they sent a person, or two people, to be there for their last year. And now I know you went on to Yale to study biophysics. I'm always fascinated by why people end up making decisions. So you were biophysics major. Why did you go into medicine? Was it your father? Well, my father and my two grandfathers were physicians, actually. So my brother was already-- he preceded me at the Wooster School, and then he went to Harvard College. I decided to go with some of the-- it was a small class. We had 16 people. Four of us went to Yale. So I decided to join the group that went to Yale. And my father thought that I should go into the sciences, but not medicine. One doctor was enough. So I started off, and I was actually doing very well in math and physics. And I was friends with a lot of premeds. But I didn't want to take any pre-medical-- the usual biochemical courses that were given at the medical school. So I decided to go with the head of biophysics major, and that suited me fine. So I started with that. And then I decided, well, you know, that's good. But let me head to medical school. So you had no choice. Actually, the really great story, I know you went to Cornell Medical School. Tell us about the lecture by Dr. Karnofsky, which I think has ended up changing oncology. Yeah, so-- yeah, actually, it was the first lectures we had in medical school as freshman. And we had-- in our 30th reunion a few years later, I talked about Karnofsky, how he inspired me to think about the clinical matters in cancer and his performance status evaluation. I remember that very well. Nobody else did. I have to tell you-- I guess it resonated with me, but not with my other mostly surgeons in my medical school. Well, this is, frankly, a recurring theme in these podcasts too, which is many of our pioneers hadn't thought about going into cancer. In fact, in those days, it almost didn't exist. And then one person made a light bulb come on. I have the same issue in my own career with Dr. Einhorn. So I think all of us need to keep in mind, you never know what influence you're going to have on a medical student. Yes, mentorship is extremely important. And going to class, face-to-face meetings are important. I know you've told me some of the stories too, but when you were at Cornell and located through Memorial, that you ran into some of the luminaries-- Joe Burchenal, Irwin Krakoff, Miriam Isaacs-- Well, I took-- well, that's partly mixed with my internship because I did my internship at Bellevue Cornell division. Yeah. And also, my clerkship. So yeah, that's when I took some electives, too, at Memorial as well. What did Miriam Isaac bring into this one? I think a lot of us know about-- Miriam Isaac was head of the metabolism group. Where did you know her from? I've just heard her name, yeah. Yeah, she was part-- Parker Vanamee and Miriam Isaac ran this physiology. It was called physiology elective. And it was ideal for a third year student. I learned everything, because you saw so many derangements that were concomitant with what was happening with the progression of cancer. But they examined all the issues regarding what led to hyperuricemia, hyperkalemia, any electrolyte imbalance. So you really learned a lot. So that almost gets to the birth of translational medicine, in many respects. We think this is new. It's not. It goes way back. Right. It goes way back. I know then you went on and finished your residency. And most importantly, you are an alumnus of the Francis Delafield Hospital. And that spurred me. I've heard this hospital's reputation my entire career. But I never knew who he was, or what it's all about. Tell us about-- Well, so the city of New York, the city of New York, they really had very good outstanding commissioners of health who decided that cancer hospitals were important to take care of New Yorkers with cancer. And they set up one at Cornell, which was called James Ewing Hospital, which was right inside Memorial Hospital. So they were-- I mean, people don't really remember the James Ewing Hospital because it was annexed into Memorial Sloan Kettering. But the one at Columbia was a separate building. And it was Francis Delafield Hospital. And it had real luminaries from the Columbia faculty, including Alfred Gellhorn, who was a professor of medicine and very charismatic. It was an outstanding group of individuals. Gellhorn presided over a group of about 10-12 internists who were dedicated to cancer and also translational research, as you say. And one of my papers that I wrote to my fellows was on hypercalcemia malignancy with Henry Heinemann, who was one of the internists. He devoted all his effort into physiology, so to speak. So it was kind of the same segue to what we I had at Memorial as a student. But the Francis Delafield Hospital had problems. They had staffing problems because the head of medicine would not send their residents to-- stop sending their residents through the oncology services-- I guess that's what it would be, if you're taking care of medical oncology services. They were in all that way. But it was the Department of Medicine at Francis Delafield. And it was kind of a bit of envy, in part, as one interprets, that Gellhorn was so popular with the students. And so there was all this internal discord with these services at Columbia and Francis Delafield, although Francis Delafield was part of Columbia. So at one point, when the residency finally stopped including, the Bellevue first division residents did rotate through. The first division residents were Columbia service at Bellevue. And they rotated through. So when Gellhorn and another name, the president of ASCO later, Jon Altman-- who was a terrific teacher whom I worked with-- he then left and went to the University of Chicago. And Gellhorn left and became dean at the University of Pennsylvania. I was told to get another job. I was there, starting to be an attending physician. And I went to Albert Einstein. So as you see, I've moved around. I've moved around a lot, but I've moved around always twice to the same place, except the University of Southern California. And there, I go every year. I've maintained my ties with the Trojans. I know that Ezra Greenspan came out of there, and Jim Holland. Jim has told several of us this story, that he was in the military. And when it ended, he thought he was going to go back and be an internist with Dr. Loeb at Columbia at the main hospital. Dr. Loeb called him, and told him there was no space. And why don't you go work at Francis Delafield? And apparently, Dr. Loeb said because somebody always gets mental problems or tuberculosis. And we have to replace them anyway. And so Holland went to Francis Delafield and took care of a young girl with leukemia who sadly died. But it changed his life. That's what made him go into oncology. I deeply regret that I won't get the interview Jim Holland. Yeah, Jim Holland was the first alumnus of that program of the Francis Delafield Hospital. And, yeah, 10 years before I went there. And Jim and I remained friends for many years. We had that friendship in common. Jim gave a-- he was an extremely articulate individual. And when Alfred Gellhorn died in 2007, he gave one of the most touching memorials in his honor. We actually interacted recently through various collaborations here in New York, with first, Jim Holland set up this New York gynecology/oncology group. He was kind of the leader in that, even though he was not involved in gynecology. But he loved to host a group-wide effort. And it happened to coalesce first in gynecologic oncology, because everybody-- they all loved Jim Holland, teaching the gynecologists, but chemotherapy in general. And he's a great leader. So he became very active in the Chemotherapy Foundation, which is a New York foundation, and spoke at the meetings. And his wife, Jenny Holland, was on the board of the Chemotherapy Foundation. We gave them-- we gave Jim an award last year in November, of the Chemotherapy Foundation, for scientific excellence. And he gave one the most unbelievable talks there. Everybody who was there, which were fellows from the New York institutions and lay audience that was there at that event, they really learned a lot by Jim's presence. And unfortunately-- unfortunately, two months later, Jimmy Holland passed away-- less than two months. And of course, Jim passed away in March of 2018. We all miss him. And any of us who had been to the Chemotherapy Foundation, especially when Dr. Greenspan was running it, I always loved that meeting. Actually, when you were at Francis Delafield, what was giving chemotherapy like? It can't be as well-organized. Well-- [LAUGHS] Well, it was organized in the lymphoma service, which John Altman ran. And I was-- so my fellowship at Francis Delafield, it was a bit unusual. It was six months of hematology, six months chief resident, six months again hematology/general oncology, then six months chief residency. So we were involved during the fellowship in running some of the-- and orchestrating the work for the medical residents. In our spare time, we did work in the clinics. And in hematology, I worked with Jon Altman. Did you guys mix up your own chemotherapy in those days? Oh, sure. Yes. Well, that went on when-- actually, that went on when I became attending here at New York University. When I came back from the NCI, we mixed the chemotherapy. So yes. Our younger colleagues don't know this. Nowadays, it's all the pharmacists do it. And the nurses hang it up and start the IVs. And in those days, you guys were on the front lines doing the whole thing, right? Yeah. I mean, we gave vinblastine primarily, but the clinic stereo was vinblastine that we gave. Because the other drugs were procarbazine, nitrogen mustard, of course. There is Chuck Martel of Mayo Clinic fame and florouracil fame. He said he used to do morning rounds to give florouracil at the Mayo Clinic. I don't know who mixed the florouracil for him. I mean, it came in already mixed. But he used to deliver the drugs. Life was different then. Actually, I want to change tracks a little bit, and that is because I know you had a lot to do with the development of supplying them when you were at CTEP at the NCI. You and I were fortunate enough to get to attend the 40th anniversary of the approval of cisplatinum by the FDA. It was held in east Lansing. And that's because Professor Barnett Rosenberg discovered it at Michigan State. Can you give me just some history of that, of what your role was, and why Dr. Rosenberg thought that cisplatinum was a good idea in the first place? Well, I mean, it goes of the drug development program, which was one of the major efforts of the chemotherapy program that was the first program that had oncology involved in it. It was mostly the team in lymphoma, with Gordon Zubrod being the head. And he's the one who recruited Fry/Frederick, and then Carbonne/DeVita group. And they were doing the clinical oncology part. Drug development was a very much part of it. And of the drugs that-- they developed drugs for some of the pharmaceutical industries because pharmaceutical industries had no trials. They had their own pipeline. Now their own pipeline had drugs like nitrosoureas, which didn't go anywhere, and dacarbazine. They were not so robust related to the screens that they used for drug development. But they also had drugs from academia and from the Department of Agriculture. And from academia, they got cisplatin, which was isolated by Barnett Rosenberg at Michigan State, as you heard in that great event that they had, the 40th anniversary of its approval. And he was running electrical currents in bacterial cultures and found that the bacteria were developing-- stopped dividing and developing filamentous forms, which were very unusual. And then he thought it was electricity at first, but then only platinum electrodes had that property. And he and his co-workers made the right assumption that it was platinum. They isolated cisdichlorodiamine dichloroplatinum which was known from a century before to be an inorganic platinum salt. That drug, when I was first at the NCI, my first tour duty as a senior investigator, was broadcasted because it had tremendous anti-tumor activity in the screens. And so when there were press releases, like it often happens, lay people call in and they want the drug for their relatives, or for themselves. And I remember answering phones and saying, no. We don't have that drug. It hasn't been given to people. But the story in 1972, the phase I study was-- I attended the ACR, where they presented. Chuck [? Kerlia, ?] from the University of Illinois, he did the first study. And it had activity. But it bumped off some kidneys and some hearing. And I said, well, who needs a drug in head and neck cancer, or Hodgkin's, where you have such terrible toxicities? Well, guess what? I was wrong. First, you deal with the cancer, then you deal with the toxicity. But it was Jim Holland. Actually, Higby, Don Higby, who worked with Jim Holland at the Roswell Park in the Holland service, who identified remarkable activity in testicular cancer. And that's what carried it. And then Larry Einhorn, of course, carried the ball on that on the development of cisplatin in testicular cancer. The group in the [INAUDIBLE] showed tremendous activity. Eve Wilshaw showed tremendous activity in ovarian cancer, but not quite curative, which is an interesting facet. And then, well, the rest is history. The FDA, that was my second time at the NCI. I had the pleasure of sitting with Vince DeVita at the FDA with Bob Kraut, who said, no, this drug is too toxic. You've got to do some randomized studies. And that was 1978 then. Vince pounded the table and said, the best thing that's happened to oncology, you can't recognize it? You know, there's something wrong with your procedures. So that led to some rethinking. And sure enough, it was approved. No need for randomized studies, given that it was curing testis cancer, but a need for educating how to deal with and cope with the toxicities. Actually, I have-- So that's the story of cisplatin. And it was even further detailed by-- when you were there at that meeting-- by Larry Einhorn and his patient. Yeah. Actually, I have three remarks to this. One is that when I was a fellow, Dr. Fry used to teach us that if the drug works and is curing cancer, we'll figure out the toxicities later. That's a little ruthless, but it's always stuck with me. Yeah. Yeah, we don't want to say it too loudly because toxicities are very important in anything you do. But of course, if you are-- you know, if it's the last resort you're looking for, for something to help the patient-- and it is helping-- you kind of have to bite the bullet sometimes. Those were the days where we had many cures anyway. The other thing that struck me at that meeting is cisplatinum is now used in more than half of all cancers-- adult cancers. I didn't realize it was that common. But that's true. The other thing that I didn't realize, that the number of publications continued in research, continued to increase more than imatinib and trastuzumab. Yeah. And that's the other thing I heard. And the final thing, just, if there are any chemists listening, to get lucky from all this-- it turns out, that trans-diaminoplatinum doesn't work, and cisdiamine does-- dichloro, I'm sorry. And the reason why is entry into the cells, is that the trans doesn't get in the cells. And the cis does. And it just goes to show how important that clinical chemistry is in our drug development. I think a lot of us forget that in the pharmacology. Right. There are actually a lot more things to learn in how the platins interact with DNA. Yes. Actually, another layer I want to go into is your importance and the really remarkable growth in the cooperative groups in the late '90s. Can you kind of give us a brief history starting in 1955, when Drs. Fry and Frederick and Holland started? And then what your role was later on in making it really take off? You're talking about the chemotherapy program? Well, weren't you involved with the qualitative groups and-- With our comparative groups, yeah. Oh, yeah, they came together. Yes, no, for sure. I was there first as an intramural person. And I was briefly on loan to the solid tumor service with Vince DeVita and George Canellos. And then I was in their new-- Paul Carbone had put me in the lung cancer study group there, that led on. So I was strictly intramural. When I returned to Einstein after to doing my service, Vince DeVita became the director of the Division of Cancer Treatment, which is the evolution of the chemotherapy program. As director of the division, he gave me a choice of couple of positions. And I actually took the cancer therapy program position as his associate director for CTEP. His predecessor had been-- my predecessor in that position had been Steve Carter. I don't know if you know about Stephen Carter. No, I met Dr. Carter. He was encyclopedic in the knowledge of all the trials that were done in the-- sponsored by the National Cancer Institute and also abroad. So he became a great face of the NCI internationally. And he spurred the development of the EORTC as well. So that was developed initially through a grant of the National Cancer Institute. So he was involved in the EORTC. But the cooperative groups had started during the leukemia program with the acute leukemia group B, which was the counterpart of acute leukemia group A, which was the intramural program. Jim Holland became the chair of the group. He was such an inspiring leader of the cooperative group. His cooperative group was amazing, to go to one of his meetings, which lasted two afternoons. He really commanded-- it was like a plenary session, and doled out all the projects in one afternoon. And then, in the second day, they kind of review whatever had developed. But other groups started. And the Eastern Cooperative Oncology Group became-- I had joined that when I had gone back to Einstein. It developed under founder Paul Carbone. He had assumed chairman-- no, Paul Carbone became the chairman later on. Initially, it was run by-- it'll come to me right now. I have a lapse on who was the group chair. But it was kind of Boston nurtured. And they were primarily devoted in solid tumors. And they started with making inroads into solid tumor beyond the acute leukemia. But in GI, for example, where I was in the GI committee, Chuck Martel did a number of studies. He ran those meetings, floated ideas. A week later-- we didn't have emails, but a week later, he had the protocol on your desk. Let me ask you a final question, to begin to tie it up here. When you were at the Delafield and then at the NCI, was there a sense that you guys were doing historic stuff? Or was it just day-to-day, same old, same old. Then you look back and say, boy, look what we did. Was there a sense that something big was happening in those days? Oh, no. There was always a sense. Well, when senior investigators, there was always a sense there are a lot of things here developing of interest, you know? And there was a full head of steam in part related to the combination chemotherapy. Now in acute leukemia, it was obvious. But the big thing about the solid tumor service since DeVita and Tom Fry, who started the work in lymphomas. Peter Wernick, George Canellos, they found that the combination chemotherapy did something in lymphomas, and also later on with, also, Jim Holland's work. And you've mentioned Ezra Greenspan. They had seen that combinations of drugs did help, to a large degree, breast cancer. Now the same drugs didn't tried to be extended-- the same principles-- to other solid tumors. It didn't work so well. But breast was somewhat sensitive to the drugs, the alkylating agents and the antimetabolites. So those were the first combinations, and the vinca alkaloids. Let me ask you this, my final question. But I've been a breast cancer guy all my life. And Cushman Haagensen, of course, is a giant. That's the name from the past. Yes. So when you were at Delafield, did he try to oppose the chemotherapy because he felt that a chance to cut is a chance to cure? I mean, he was one of the biggest knives of all time. Yes. Actually, no, he opposed it for different reasons. I never understood why. He didn't only oppose chemotherapy, he opposed hormone therapy, which was coming along. Because he thought that any sex hormones were detrimental to the course of disease. But it was also mostly rivalry with a medical service, I think. Because we saw responses. I did my first trial with progestational agents. So I did some clinical trials, actually, when I was a fellow. So we published an observational series of patients treated with medroxyprogesterone acetate, and presented at the American College of Physicians in '67. So you know, he opposed Gellhorn's intervention in breast cancer medical intervention. He liked to give steroids. And we used to see the patients because the patient developed diabetes. So that's how we got involved in some of the disseminate at the patients with metastatic breast cancer. He wouldn't refer them. So I got involved because I saw a lot of diabetes. And then we started our own treatments. We bonded with the patients and started our own treatments. Again, a recurring theme is how much courage it took for you and your predecessors to do what you do. And the confrontation, if not hostility, between the surgeons. I have to say, that what that really does is it brings up Bernie Fisher and Umberto Veronesi, and the courage they had to adopt systemic therapy as opposed to obstruct it. I don't think our younger colleagues are aware of the battle. Oh, yeah, no. Bernie deserves a lot of credit. And I can tell you of arguments he had with Jerry Urban and other surgeons when he came to a meeting in New York. And Sam Hellman was there. He said, Bernie, we agree with you. I think it's taken us some time to process what you just-- the great thing you have done, to rely on other than surgery. Because they came after him, even I'm talking early 1980. Oh, I was at a meeting. I was at a meeting maybe '83 or '4. It was the first time I'd ever met Dr. Fisher. And he and Urban were sharing a podium. I thought there was going to be a fistfight. Yes. I mean, it was really contentious. And that was an eye-opener for me, where I thought, there's a surgeon up there telling us we should do things that will put him out of business. That's a very interesting approach. Well, yes. And the one thing about Bernie Fisher, he understood trials. And I remember, they said-- Jerry Urban said, why do you think that that curve isn't just going to go down and plummet? He said, it's called probability, Doctor. [CHUCKLES] All right. Well, we've run out of time. I hate to say that because these are great stories. But I want to thank you for taking time. Thank you, Dan, for the interview, for sure. And we do share some common background. And we didn't get to talk about all the international things that came out of the National Cancer Institute. As Jim Holland said in that congressional hearing, the National Cancer Institute was the best international weapon we have had. Yeah, I think that's a great point. And I do regret we've run out of time here. Maybe we can do that in another interview. But I want to also thank you for all you've done for the field and the hundreds of people you've trained. I don't go anywhere where I don't bring up your name, and somebody goes, oh, yeah. I worked with that guy. Well, that's a motive a great satisfaction, I have to say, for sure. It takes just the ability to listen to what your fellows are saying and responding to them. Yeah. That's been my secret. And you're very good at that. I've seen you in action. So thanks again. I appreciate this, and look forward to seeing you soon. Thank you, Dan. I appreciate very much all your questions, and your interview, and your friendship. [MUSIC PLAYING] Until next time, thank you for listening to this JCO's Cancer Stories, the Art of Oncology podcast. If you enjoyed what you heard today, don't forget to give us a rating or a review on Apple Podcast, or wherever you listen. While you're there, be sure to subscribe so you never miss an episode. JCO's Cancer Stories, the Art of Oncology podcast is just one of ASCO's many podcasts. You can find all the shows at podcast.asco.org. [MUSIC PLAYING]

Mark Butcher and John Altman join Yas Rana in an Ashes special. They look back to the World Cup final and exchange stories about their time in and around the England and Australia sides of the 90s and early 2000s. Taha Hashim speaks to Yas about England's squad for the Ireland Test.

Judy Carmichael interviews John Altman

With over 40 scores to his credit, John Altman has had a distinguished career, not only in film music but has an arranger, songwriter and musician. In this episode, John shares his favorite scores by other composers as well as a few favorites of his own. He shares some interesting behind the scenes tales on scoring and provides a fascinating account of his work on the James Bond Film "Goldeneye".

John Altman (AKA Nasty Nick from Eastenders) was our first guest in the studio this afternoon as he treated us to a drum solo on the desk and dreamed about appearing in other soaps as Nick Cotton! Following John was international Chef Roze Traore, who discussed how he started cooking and his plans for world domination. Producer Nat also swooned and Ian installed a klaxon in an attempt to silence her

John Altman (AKA Nasty Nick from Eastenders) was our first guest in the studio this afternoon as he treated us to a drum solo on the desk and dreamed about appearing in other soaps as Nick Cotton! Following John was international Chef Roze Traore, who discussed how he started cooking and his plans for world domination. Producer Nat also swooned and Ian installed a klaxon in an attempt to silence her

In Episode 19 we continue our ambitious attempt to analyse every James Bond score ever. Having covered the Connery classics in Episode 18, we’re now onto the 1970s, 1980s, and even the early 1990s, covering Moore, Dalton, and a little bit of Brosnan as James Bond goes from funk to disco to acid jazz and even a little early hip-hop. Join us as we look at some of the kitschiest Bond music out there – and, some of the all-time greats. Episode notes: 3:38 – Roger Moore’s more George (Aston) Martin Bond music 9:11 – The 1970s funk boat chase 12:45 – Nick has a problem with The Man With the Golden Gun’s parallel motion 16:43 – The Spy Who Wrote A Fantastic Opening Song 18:10 – James ‘Disco Stu’ Bond 24:30 – The singing pyramids 28:33 – The Space Who Loved Me 32:45 – Bossa, James Bossa 35:38 – Bill Conti’s For Your Funk Only 43:40 – John Barry’s finale: Octopussy, A View To A Kill, and The Living Daylights 49:12 – Dalton’s daylight drum machine 54:50 – Michael Kamen’s License to Trill 1:01:04 – Bond’s power ballad romance 1:04:50 – Serra’s synth sound for Goldeneye and the sonic reinvention of James Bond 1:13:34 – Acid James 1:17:40 – Escaping the Archives 1:19:04 – Goldeneye’s Tank Chase and John Altman’s replacement music We love to hear from our listeners – get in touch via Twitter, Instagram, and Facebook, and if you like The Art of the Score, please take a moment to subscribe, rate and comment.

John Altman began his musical career at age 3 with Judy Garland at the London Palladium! Commencing his recording and live career in the late 60’s as an in-demand saxophonist - he has performed with many major figures in music, including Eric Clapton, Sting, Phil Collins (all of whom performed in his band, the Secret Police, an all star aggregation specially assembled for the Secret Policeman’s Ball), Jimi Hendrix, Nick Drake, Muddy Waters, Bob Marley, Jimmy Page, Little Richard, Prince, and Van Morrison and Hot Chocolate (for both of whom he functioned as musical director) and many more. He has recently contributed saxophone solos for the new albums by Rick Astley, Chuck D and Goldie. To learn more about this ASMAC Luncheon with special guest, John Altman, go to: http://www.asmac.org/john-altman-luncheon-august-19-2009

Lees hosted a Film & TV panel live from Geekedfest 2015. This previously lost episode featuring our panel with John Challis from Only Fools And Horses, John Altman from Eastenders and the lovely Virginia Hey from Farscape, among others as they took questions from our live audience and tell stories from their vast careers. For the intro Lees is joined by Doctor Squee, host of Gallifrey Stands Podcast. Special thanks to Iain Shaw for recording all our live sessions at Geekedfest.Brought to you by Sin City Comics sincitycomics.co.uk

John Altman (December 5, 1949, London) is a British film composer, music arranger, orchestrator and conductor, and currently serves on the ASMAC Board. He won a Primetime Emmy Award for Outstanding Music Composition for a Limited Series, Movie or a Special (Original Dramatic Score) and was nominated for BAFTA Award for Best Film Music. His credits include music for Monty Python, James Bond movies and he served as music director for Van Morrison and Prince's Trust Concerts. Introduced by Ray Charles. (47:52)

Lees had the chance to sit down with Ian McElhinney who we all love as "Ser Barristan The Bold" on Game Of Thrones. He shares his vast knowledge on the Game Of Thrones books, and talks in depth about the process of putting together a television show set in such a vast and rich universe and as well as what it's like to "quit like a boss" he also takes questions from our live audience. For the complete Geekedfest experience be sure to check out Gallifrey Stands Podcast episode 69 with Doctor Squee where you can listen to the Q&A with John Levene and our panel with Simon Fisher-Becker, Sarah Louise Madison, and Matthew Dale all stars from Doctor Who. Also check out our follow up Get Geeked episode featuring our panel with John Challis from Only Fools And Horses, John Altman from Eastenders and the lovely Virginia Hey from Farscape as they took questions from our live audience. Special thanks to Iain Shaw for recording all our live sessions at Geekedfest. Brought to you by Sin City Comics in Cwmbran and online at sincitycomics.co.uk 

Composer and saxophonist John Altman joins Alyn Shipton to pick the best records by saxophonist Al Cohn. As well as his solos albums and his lengthy association with fellow tenorist Zoot Sims, the programme covers Cohn's work with Joe Newman and Freddie Green, and as an arranger for Gerry Mulligan's Concert Jazz Band.